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Kidney International (2019) 95, S1–S33integrated ESKD care, including 92 individuals from around
the globe with diverse expertise and professional
backgrounds. The attendees were from 41 countries,
including 16 participants from 11 low- and lower-middle–
income countries. The purpose was to develop a strategic
plan to improve worldwide access to integrated ESKD care,
by identifying and prioritizing key activities across 8
themes: (i) estimates of ESKD burden and treatment
coverage, (ii) advocacy, (iii) education and training/
workforce, (iv) ﬁnancing/funding models, (v) ethics, (vi)
dialysis, (vii) transplantation, and (viii) conservative care.
Action plans with prioritized lists of goals, activities, and
key deliverables, and an overarching performance
framework were developed for each theme. Examples of
these key deliverables include improved data availability,
integration of core registry measures and analysis to informS1
Table 1 | Deﬁnitions of ESKD, supportive care, and
comprehensive conservative care
ESKD
 The last stage of CKD and when KRT (hemodialysis, peritoneal dialysis,
or kidney transplant) could be considered to improve longevity or
quality or life.
Supportive care
 Involves services aimed at improving the HRQoL of patients with
established CKD.
 Based on the principles of palliative care, which is deﬁned by the World
Health Organization as an approach that improves the HRQoL of pa-
tients and their families facing problems associated with life-
threatening illness, through the prevention and relief of suffering by
means of early identiﬁcation and impeccable assessment and treatment
of pain and other physical, psychosocial, and spiritual problems.
Conservative care
 Can be an alternative to KRT and delivered in 1 of 2 settings:
B As “comprehensive conservative care,” where conservative care is
either chosen or medically advised. This is planned, holistic, person-
centered care that includes the following:
 Interventions to delay progression of kidney disease and
minimize risk of adverse events or complications
 Shared decision making
 Active symptom management
 Detailed communication including advance care planning
 Psychological support
 Social and family support
 Cultural and spiritual domains of care
Of note, comprehensive conservative care does not include dialysis.
B As “choice-restricted conservative care,” where resource constraints
have prevented or limited access to KRT and, therefore, while not
chosen, conservative care is preferable to no care at all.
CKD, chronic kidney disease; ESKD, end-stage kidney disease; HRQoL, health-related
quality of life; KRT, kidney replacement therapy.
Modiﬁed from Davison SN, Levin A, Moss AH, et al. Kidney Disease: Improving Global
Outcomes. Executive summary of the KDIGO Controversies Conference on Sup-
portive Care in Chronic Kidney Disease: developing a roadmap to improving quality
care. Kidney Int. 2015;88:447–459.11
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD caredevelopment of health care policy; a framework for
advocacy; improved and continued stakeholder
engagement; improved workforce training; equitable,
efﬁcient, and cost-effective funding models; greater
understanding and greater application of ethical principles
in practice and policy; deﬁnition and application of
standards for safe and sustainable dialysis treatment and a
set of measurable quality parameters; and integration of
dialysis, transplantation, and comprehensive conservative
care as ESKD treatment options within the context of overall
health priorities. Intended users of the action plans include
clinicians, patients and their families, scientists, industry
partners, government decision makers, and advocacy
organizations. Implementation of this integrated and
comprehensive plan is intended to improve quality and
access to care and thereby reduce serious health-related
suffering of adults and children affected by ESKDworldwide.
Kidney International (2019) 95, S1–S33; https://doi.org/10.1016/
j.kint.2018.12.005
KEYWORDS: advocacy; conservative care; dialysis; end-stage kidney disease;
ESKD; funding; training; transplantation; universal health coverage
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K idney disease is recognized as a global public healthproblem, a risk multiplier for many other conditions,and for its association with cardiovascular disease
(CVD), diabetes, and infections. Chronic kidney disease
(CKD) progresses to end-stage kidney disease (ESKD), which
requires kidney replacement therapy (KRT; dialysis or kidney
transplant) or comprehensive conservative care (nondialytic
care) (Table 1 and Figure 1). The prevalence of KRT for
ESKD is rising worldwide, and the fastest growth is occurring
in low-income countries (LICs) and lower-middle–income
countries (LMICs).1
Soon after it became clear that dialysis could be performed
as a chronic therapy in the 1960s, insufﬁcient funding emerged
as the major barrier to accessing treatment. The presumption
that funding for dialysis would allow relatively young,
employed, taxpaying members of society with ESKD to be
rehabilitated and return to work led to a public debate in the
US that culminated in passage of the Social Security Amend-
ment by Congress in 1972.2 Removal of ﬁnancial barriers laid
the foundation for rapid expansion of dialysis programs in the
US and later in the rest of the developed world—to the extent
that access to dialysis is now used globally as a benchmark for
societal willingness to pay for medical care.3
As the magnitude of ESKD burden became apparent, with
its ﬁnancial consequences to the health system, the need to
prioritize prevention was realized4,5 (Figure 1). Directing re-
sources to prevention of CKD and ESKD rather than provi-
sion of ESKD care is much more cost-effective. However, even
optimal prevention and treatment of kidney disease will not
obviate the need for KRT. It is estimated that in 2010, 2.62
million people were receiving KRT worldwide for ESKD, andS2that a further 2.3 to 7.1 million, mainly in LMICs, required
KRT but died for want of it.1 Dialysis, in particular hemo-
dialysis (HD), is commonly considered to be the default
treatment for ESKD, but not all patients are suitable candidates
or will beneﬁt from it. Furthermore, several large registry
studies and systematic reviews have conﬁrmed that in appro-
priate patients, transplantation provides survival advantage and
better quality of life, and is more cost-effective than dialysis.6–9
Hence, in the absence of resource constraints, ESKD care
should ideally be available as an integrated mix of peritoneal
dialysis (PD), HD, transplantation, and conservative care
(nondialytic care), and patients should be able to choose and
transition between the different modalities (Figure 1). Non-
resource determinants of choice of modality for ESKD care
include age, comorbidity, life expectancy, and lifestyle consid-
erations. For suitable candidates, kidney transplant is the best
form of KRT, and among the rest, a signiﬁcant proportion are
best treated with conservative care. In 2015, 84,347 kidney
transplants were performed worldwide (1950 were pediatric;
i.e., patients < 15 years old), representing an increase of 5.5%
over 2014.10 However, the number of transplants falls far short
of the current global demand.
Health care professionals and administrators must balance
their responsibilities to the health care system with those toKidney International (2019) 95, S1–S33
Figure 1 | End-stage kidney disease pathways.
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prioritization of KRTmust be balanced against other pressing
societal needs such as sanitation, clean water, prevention and
treatment of infectious diseases and noncommunicable dis-
eases (NCDs; including diabetes, hypertension, CVD, and
CKD itself), and reproductive and pediatric health. Thus,
how ESKD care is provided for individual patients will be
decided based not only on their health condition, their family,
and their social and ﬁnancial resources, but also by the health
care setting in which they receive care.
Brief methods
In view of the need for a cohesive plan to address the chal-
lenge of ESKD, especially in emerging economies, the Inter-
national Society of Nephrology (ISN) organized a summit in
Sharjah, United Arab Emirates, in March 2018. The summit
was co-chaired by Drs. Simon Davies, Fred Finkelstein, David
Harris, and Vivekanand Jha, and participants from around
the globe included 92 individuals with diverse expertise (ad-
ministrators, clinicians, clinical and translational researchers,
epidemiologists, industry scientists, nurses, nurse practi-
tioners, pediatric nephrologists, an ethicist, a health econo-
mist, a patient, and a representative from the World Health
Organization [WHO]). The attendees were from 41 countries,
including 16 from 11 LICs and LMICs. The purpose of the
meeting was to develop a roadmap to improve worldwide
access to integrated ESKD care. Steps in achieving this goal
include understanding current global differences in ESKD
care; considering ethical, technological, human resource,
ﬁnancial, and cultural issues involved in the expansion of
ESKD care; and supporting development of all aspects of just
and equitable ESKD care provision in LMICs. The meetingKidney International (2019) 95, S1–S33provided opportunities to deﬁne and design concrete strate-
gies to ﬁll gaps in knowledge and practice, and to create a
performance framework to evaluate progress over time.
Participants met for 2.5 days to develop the plan, which was
based on 8 themes predeﬁned by the 4 co-chairs (Table 2),
under the overarching domains of advocacy, sustainability, eq-
uity, and integration. All delegates participated in 2 of 8 working
groups, each of which addressed a single area of focus. Pre-work
for the meeting consisted of identiﬁcation of key issues, sup-
porting literature searches, and facilitated discussion. Using an
iterative process, each group produced a prioritized list of key
issues, goals, activities, and deliverables.
The themes and areas of focus are discussed in the
following sections, noting the gaps in knowledge and practice,
and listing activities recommended to address the gaps. The
performance framework is designed to track activity progress
over time. Recognizing the diversity of health care systems in
LMICs, the participants emphasized the need to individualize
and tailor the implementation of proposed action steps ac-
cording to local needs, culture, geopolitical climate, and
available resources. Participants also stressed the value of
sharing experiences in platforms such as the summit to
evaluate progress and make course corrections. Participants
agreed that what is important for the patient would be a key
determinant of any such plan.
Theme 1: estimates of ESKD burden and treatment coverage.
Explain the reasons for and monitor global differences in the
incidence and prevalence of ESKD, ESKD care, and modality
of ESKD care
Known KRT prevalence varies more than 1000-fold across the
globe from close to zero per million population (pmp) inS3
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to over 2000 pmp in parts of North and East Asia (e.g., 3317
pmp in Taiwan and 2529 pmp in Japan), suggesting large
inequities in global access to KRT.12–14 Four-ﬁfths of all pa-
tients with ESKD treated with KRT reside in North America,
Japan, or Europe.12,15,16
Inequities are also evident in the relative availability of
different forms of KRT (Figure 2 and Supplementary
Tables S1 and S2). For example, PD, useful for adults but
particularly appropriate for children, is available in only 29%
of LICs.13,14 HD services may vary in different regions of the
same country and also between rural and urban areas. The
quality of delivered dialysis varies widely, as will be discussed
below, but its assessment is difﬁcult and unreliable. Kidney
transplantation, which for suitable candidates provides the
best survival, quality of life, and is most cost-effective,17 is
available in only 36% of African countries and worldwide in
only 12% of LICs.13,14 In those that do provide kidney
transplantation, rates vary from <1 pmp in Bangladesh to 71
pmp in the Mexican state of Jalisco.12 There are signiﬁcant
differences in transplantation rates even within countries
falling in the same income category. Living donor trans-
plantation is the most common type of transplantation
available in LMICs.
Socioeconomic factors are the major drivers of the observed
differences in the epidemiology of ESKD, in particular ESKD
care. KRT prevalence is highly correlated with national
wealth1,16 (Figure 2 and Supplementary Tables S1 and S2).
Approximately 93% of individuals receiving KRT in 2010
resided in high-income countries (HICs) or upper-middle–in-
come countries (UMICs), such that there was a 70-fold greater
prevalence in the rates of KRT in these countries compared with
their LMIC counterparts.1,18,19 The most important barrier to
KRT in LICs and LMICs is the high cost, which the patients
have to pay from their own resources. The annual costs of
dialysis have been reported to be 7- to 48-fold higher than
average annual incomes.20 The high cost leads to premature
withdrawal of KRT, premature death, and severe ﬁnancial debt
for surviving family members, particularly in LICs.21,22
Other factors inﬂuencing the epidemiology of ESKD care
are summarized in Figure 3. Patient characteristics, such
as female gender, older age, indigenous racial origin,Table 2 | ESKD summit themes and areas of focus
Theme
Estimates of ESKD burden and
treatment coverage
Explain the reasons for and monitor g
Advocacy Develop an app
Education and training/
workforce
Develop locally app
Financing/funding models Develop ﬁnancial strategies
Ethics Enuncia
Dialysis Deﬁne, recommend, apply, and deve
stand
Transplantation Deﬁne the key considerations for exp
Conservative care Deﬁne the key considerations and de
ESKD, end-stage kidney disease; LMIC, lower-middle–income country.
S4socioeconomic status, poor health literacy, and high burden
of comorbidities have all been associated with reduced access
to and/or use of KRT.12,23–25 In most African and South and
Southeast Asian countries, children’s access to dialysis is
severely restricted.25,26 Even among and within HICs, there
are wide variations in the incidence and prevalence of ESKD
treated with KRT not explained by differences in national
income and in part related to the cause and severity of disease
and age of the patients.1,27
The highly variable availability, coverage, and quality of
ESKD registries prevent proper understanding of the
epidemiology of ESKD and ESKD care around the world.
This is particularly true in LICs, where nondialysis CKD,
dialysis, and kidney transplant registries are available in only
6%, 18%, and 0% of countries, respectively.13,14,28 African
(35%) and South Asian (40%) countries have the lowest
frequencies of dialysis registries and are also the areas where
the gaps between treated and untreated ESKD are high-
est.13,14 Similarly, only 19% of African countries and 40% of
South Asian countries have a transplant registry.13,14 Stra-
tegies to address this gap are discussed below and summa-
rized in Table 3.
Improve estimates of the incidence and prevalence of ESKD
and ESKD care, including capturing KRT modality and out-
comes. A cornerstone of understanding the global ESKD
treatment gap is establishing robust health information sys-
tems in each country as a means to deﬁne CKD and ESKD
burdens, guide resource allocation to areas of need, identify
barriers to accessing KRT, capture costs of treatment, and
monitor KRT health outcomes, thereby informing KRT ser-
vice planning and enabling policy development (including
CKD prevention and control). A number of LMICs are in the
process of setting up national dialysis registries; the ISN is
supporting these efforts through the SharE-RR project
(https://www.theisn.org/advocacy/share-rr), which will
develop a resource that supports establishment of a renal
registry to support advocacy, quality assurance, and research.
This project will facilitate sharing of a data dictionary, registry
policies, procedures, governance structures, databases, data
sets, technology platforms, ﬁles, and consent processes. Sur-
veys of existing registries will inform the establishment of a
minimum data set to permit benchmarking between registriesArea of focus
lobal differences in the incidence and prevalence of ESKD, ESKD care, and
chosen modality of ESKD care
roach to advocate for integrated ESKD care in LMICs
ropriate strategies to enhance health workforce capacity
and funding models to ensure equitable integrated ESKD care
te ethical principles surrounding ESKD care
lop a monitoring framework for minimum and optimal safety and quality
ards for peritoneal dialysis and hemodialysis
ansion of kidney transplantation as a component of integrated ESKD care
velopment of conservative care as a component of integrated ESKD care
Kidney International (2019) 95, S1–S33
ab
P value
P value
P value
P value
P value
P value
P value
P value
P value
P value
P value
P value
Figure 2 | (a) Prevalence and (b) incidence rates of end-stage kidney disease (ESKD) (treated), dialysis, hemodialysis, peritoneal
dialysis, kidney transplantation (Tx), and donor type in high-income countries (HICs) versus non-HICs. Designation as non-HIC is
based on World Bank country classiﬁcation and includes 3 country groups: upper-middle-income countries (UMIC), lower-middle–income
countries (LMIC), and low-income countries (LIC). ESKD includes all kidney replacement therapy components: dialysis þ transplant. Dialysis
includes all dialysis treatment modalities: hemodialysis þ peritoneal dialysis. Data source: Supplementary Table S2. pmp, per million
populations.
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Figure 3 | Factors related to national, regional, and global variations in the incidence of treated and untreated end-stage kidney
disease. CKD, chronic kidney disease; GDP, gross domestic product; HIS, health information system; ISN, International Society of Nephrology;
KRT, kidney replacement therapy; WHO, World Health Organization.
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD careand to monitor the quality of care and outcomes. A minimum
data set will (i) help health care professionals and people with
ESKD make better-informed treatment decisions; and (ii)
capture serious health-related suffering in people with ESKD
for inclusion in global health reports.
Renal registries in countries and regions with low or relatively
limited resources, such as Chad, Guinea, Niger, Tunisia, South
Africa, Thailand, Malaysia, and several countries in Latin
America (Bolivia, Colombia, Cuba, Ecuador, El Salvador,
Guatemala, Honduras, Mexico, Nicaragua, Paraguay, Peru,
Dominican Republic, and Venezuela) have demonstrated the
potential of registries to highlight inequitable KRT access and
help support policy decisions in favor of providing additional
resources for ESKD care.13,14,29–34 For instance, the huge gap in
access to KRT between the private and public sectors demon-
strated by the South Africa Renal Registry35 is being used to
advocate for increased access to KRT in the public sector in
South Africa. These experiences should be drawn upon to help
establish successful registries in other resource-limited countries.
Another possible strategy is incorporating data from
resource-limited countries into existing registries, as has
happened on occasion with North African countries contrib-
uting to the European Renal Association – European Dialysis
and Transplant Association (ERA-EDTA) Registry30,33 and the
United States Renal Data System (USRDS) registry.12 The
increasing number of countries included in the Latin American
Registry of Dialysis and Transplantation (currently collecting
information on 20 countries of the region) is another example
of the incorporation of resource-limited countries into existingS6registries.34 Paciﬁc Island countries (e.g., Fiji) could leverage the
infrastructure and collaborative expertise of the Australian and
New Zealand Dialysis and Transplant (ANZDATA) Registry.
Recently, agreement was reached between the African Associa-
tion of Nephrology and the African Paediatric Nephrology
Association to establish the African Renal Registry, which will
use the shared web-based technology platform and common
data dictionary of the South African Renal Registry.30
Registry data could be linked with geographic information
systems to identify ESKD “hot spots” and areas where there
are major mismatches between KRT supply and demand.36
Registry data should be further enhanced by linkages with
country population data, death registries, and other mortality
data sets (e.g. Global Burden of Disease data), where possible.
Registry output and reports should also be freely accessible
online to maximize reach, transparency, and impact.30,37
Benchmarking will be facilitated by developing standard-
ized deﬁnitions and terminology (data dictionary) for regis-
tries and also by the establishment of a minimum to be
collected by all renal registries. For example, ESKD is vari-
ously deﬁned around the world, ranging from absolute
requirement for KRT to estimated glomerular ﬁltration rate <
15 ml/min per 1.73 m2.38 This deﬁnition and other important
variables collected in registries need to be harmonized.
Deﬁning conservative care for capture by registries has proven
challenging, with limited data available on numbers treated
conservatively (nondialysis care) and the components and
quality of conservative care. It is necessary to deﬁne the
initiation of conservative care if registries are to measure itKidney International (2019) 95, S1–S33
Table 3 | Explain the reasons for and monitor global differences in the incidence and prevalence of ESKD, ESKD care, and
modality of ESKD care
Activities Partners Deliverables
Improve estimates of the incidence and prevalence of ESKD and ESKD care, including capturing KRT modality, and outcomes
Establish and enable ESKD registries in all
countries:
- Make outputs, industry databases, and reports
freely accessible online
- Integrate all aspects of ESKD care (adult and
pediatric) into existing and new registries
- Link with geographic information systems, death
registries, or other mortality data sets
- Explore mobile technology to access individual
data
- Compare ESKD registries with national popula-
tion data
- Supplement with observational studies (e.g.,
DOPPS)
- Develop a common, standardized data
dictionary
Existing renal registries, patient and
parent organizations, ISN and
other national and regional
professional associations, local
and national health service
providers and funders, industry,
SharE-RR committee, experts in
data linkage
- Survey and inventory of existing renal regis-
tries (as part of GKHA and SHarE-RR projects)
- ESKD Care Registry resource hub
- Published map of ESKD “hot spots” within
regions and countries
- Collated reports of the proportion of patients
dying from untreated ESKD in each country
- Published factors associated with reduced
access to KRT
- Publicly searchable registry and database
reports
- Publicly available data dictionary
Improve measurements of organ donation,
transplantation, and outcomes
CTS, established registries,
ONT-WHO GODT
- All countries contributing to registries
- Published annual outcome statistics
of donors and transplant recipients
- All member states submitting data
to ONT-WHO GODT
Develop scholarships for training in epidemiology
and registries
ISN and other national and regional
professional associations, local
and national health service
providers and funders, industry
- ISN and other professional association
scholarships
CTS, Collaborative Transplant Study; DOPPS, Dialysis Outcomes and Practice Patterns Study; ESKD, end-stage kidney disease; GKHA, Global Kidney Health Atlas; ISN, Inter-
national Society of Nephrology; KRT, kidney replacement therapy; ONT-WHO GODT, Spanish Transplant Organization-World Health Organization Global Observatory on
Dialysis and Transplantation; SharE-RR, sharing expertise to support the set-up of renal registries.
DCH Harris et al.: Global access to ESKD care I SN pub l i c a f f a i r sand report on quality. For similar reasons, it is necessary to
agree on a deﬁnition for discontinuation of dialysis.
The prime focus of renal registries should shift from
being modality-centered to person-centered KRT so that
the journeys of patients with ESKD can be followed,
monitored, and mapped along the continuum of ESKD
care. Key patient-centered performance indicators should
be captured to measure quality of care, including conser-
vative care, which is often recorded poorly or not at all. In
the same vein, registries should be integrated within
countries and regions, such that pediatric and adult regis-
tries are combined and all forms of ESKD care (including
dialysis, transplantation, comprehensive conservative care,
and choice-restricted conservative care) are captured.
Scholarship opportunities to speciﬁcally provide registry
training and experience could help in the development and
implementation of local registries, as had been demon-
strated by previous Latin American Society of Nephrology
and Hypertension (SLANH)-European Renal Association-
European Dialysis and Transplant Association (ERA-
EDTA) fellowships in epidemiology and registries.
The scope of data that should be collected and collated is
more than can be captured routinely by registries alone.
Multiple sources of data, some of which can be linked to
registry data, can be obtained during care of individual pa-
tients and from health systems. Examples include routinely
collected clinical data and data obtained from dialysis ma-
chines and other equipment. Such data can be used toKidney International (2019) 95, S1–S33evaluate ESKD care at multiple levels, including that of the
individual patient, kidney unit, and geographic region.
Theme 2: advocacy. Develop an approach to advocate for
integrated ESKD care in LMICs
Countries are responding to the challenge of kidney disease
and/or failure in different ways,39 with variable provision of
the components of a kidney care strategy (prevention, sup-
portive care, conservative care, kidney transplantation, and an
appropriate mix of dialysis modalities). The variability in
approaches may be due to differences in the burden of dis-
ease, available human or ﬁnancial resources, cost structures
(e.g., relative cost of labor vs. supplies), cultural and religious
considerations, political context, and competing interests
from other stakeholders (including governments, other
payers, patients and families, drug and device companies,
dialysis providers, nephrologists, and other health care
workers).40 Decisions to establish dialysis services without
sufﬁcient consideration of the other components of a kidney
care strategy are of particular concern — and are often made
without effective representation and guidance from the kid-
ney care community.
The current approach to kidney disease in many countries
is neither sufﬁcient (in terms of providing equitable access to
high-quality care) nor sustainable (for the patient, health
system, economy, and society) and demands the urgent
attention of governments, policy makers, and the medical
community.S7
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD careThere is currently no agreed-upon global framework or
approach that LMIC governments can use to establish and/or
scale up programs to prevent and treat CKD. Many of the
existing WHO “best buys” for NCDs41 will help to prevent
progressive loss of kidney function and thus the burden of
ESKD. However, there is no agreed “best buy” list of diag-
nostic tests or treatments for kidney diseases. Moreover, the
CKD burden in many geographic areas is not explained by
the commonly recognized risk factor clusters against which
the current NCD best buys have been developed. This in-
formation would be useful to governments and health au-
thorities that seek to develop integrated kidney care
programs. In addition, there is a lack of information on how
to successfully implement such programs. Case studies that
summarize lessons learned from the global experience with
kidney care programs would be a useful advocacy tool and are
being developed. If selected carefully, such tools could be used
by stakeholders to advocate for an integrated approach to
kidney care (including ESKD) within a context of universal
health coverage (UHC) and with an emphasis on preventive
care. Activities to advocate for integrated ESKD care are
discussed below and summarized in Table 4.
Develop a framework that LMIC governments can use to
establish and/or scale up programs for preventing CKD and
providing ESKD care. The high cost of dialysis and the
morbidity and mortality associated with ESKD emphasize the
high value of primary and secondary prevention. The
expertise, medications, and diagnostic tests required to slow
or prevent progressive kidney function loss are relatively
inexpensive and could be scaled and spread in conjunction
with other public health programs for prevention and control
of chronic diseases.42 Given that the cost per quality-adjusted
life year (QALY) associated with providing such preventive
care is markedly more favorable than dialysis care,42 it is
rational to prioritize publicly funded preventive care rather
than publicly funded KRT. The ISN therefore accords the
highest priority to prevention, and all capacity-building
programs of the ISN and its partners are predicated on the
requirement that there be a focus on prevention and other
early interventions. Similarly, because not all patients with
ESKD will beneﬁt from and/or have access to KRT, expanded
access to comprehensive conservative care (see theme 8) will
improve patient outcomes and the experience of patients and
families, and providing access to publicly funded compre-
hensive conservative care should receive priority.
When KRT is contemplated, kidney transplantation offers
for suitable patients the best outcomes at the lowest cost,
compared with dialysis, at least when provided in the right
conditions.6 Although HD is often considered ﬁrst by coun-
tries seeking to develop a dialysis program, PD usually offers
similar outcomes at lower costs to the health care system.43,44
PD is especially appropriate for adolescents, children, and
infants. Assuming that a well-run dialysis program can be
established, the choice to favor PD over HD or to allow free
choice by the patient should be supported by robust local
health economic studies (theme 4).S8Although these general principles for resource allocation
(summarized in Table 5) are widely accepted, there are some
practical barriers to their application. First, kidney trans-
plantation requires multiple ancillary components (e.g., surgical
expertise and facilities and access to tissue-typing laboratories)
that may be difﬁcult for LMICs to develop and sustain.45
Because these services all involve certain ﬁxed costs that are
amortized across the total number of transplants done, the cost
per transplant can be unreasonably high in settings where pro-
grams are new and/or perform low numbers of transplants. One
option for countries in this position could be to partner with
countries with more established programs, which would allow
for shared resources, access to specialized training, and a
pathway to improve local capacity. This assumes that adequate
postoperative and chronic follow-up can be done locally. Sec-
ond, patients whose transplants experience primary nonfunction
or eventually fail will die of ESKD without dialysis support.
Therefore, even in settings where kidney transplantation is
successfully implemented as the preferred mode of KRT, dialysis
capacity will be required. Third, although PD is generally less
expensive than HD, there are settings where this is not the
case—especially those where PD ﬂuids and supplies are expen-
sive (e.g., due to tariffs or lack of competition), or where skilled
labor is relatively cheap (favoring HD because nursing care is a
key driver of costs for this therapy but is not much needed to
provide PD).46 Therefore, ﬂexibility is needed in applying these
principles in different settings.
The 4 principles (in Table 5) are supported by evidence,
but such evidence is not always summarized in a format that
is useful to decision makers, may not apply to all LMIC set-
tings, and may not have been recently updated. To be maxi-
mally useful to decision makers in LMICs, new evidence
summaries (rapid reviews, systematic reviews, and economic
analyses) are required that will provide updated and accessible
information to support decision-making on kidney care
programs. In addition, data that facilitate application of
general principles in real-world settings would be beneﬁcial.
For example, identifying the threshold cost for PD ﬂuids at
which PD becomes more expensive than HD would help to
identify settings in which principle 4 (Table 5) may not apply.
Similarly, local information on the incremental cost of PD
compared with HD would help decision makers to under-
stand the net ﬁnancial costs of a “free choice” strategy to
dialysis modality selection. Therefore, there is an urgent need
to produce and disseminate these summaries in partnership
with end users.
There are several models that could be considered for
organizing and funding kidney care programs, each with their
own advantages and disadvantages. A summary of these
models would be a useful adjunct to the summary of evidence
related to the clinical services that should be provided and
should be developed and disseminated in parallel with the
former. Table 6 indicates a potential pathway for countries to
develop a model of integrated kidney care, based on the
experience of successful initiatives in countries such as Taiwan
and Japan.Kidney International (2019) 95, S1–S33
Table 4 | Develop an approach to advocate for integrated ESKD care in LMICs
Activities Partners Deliverables
Develop a framework that LMIC governments can use to establish and/or scale up programs for preventing CKD and providing ESKD care
- Identify and/or produce literature syntheses to support
the development of a national kidney care program
- Develop a tool that describes and justiﬁes the principles
behind establishing a national kidney care program
Cochrane Collaboration, university-based
research groups
WHO, government ofﬁcials, nephrology
societies, kidney foundations, patient
groups, academia/health economists
- Document library
- Primary rapid reviews, systematic
reviews, and economic analyses
- Scientiﬁc publication
- Brief technical report
Support stakeholders in advocating for integrated kidney care programs within their countries
- Develop and disseminate an advocacy tool kit for
stakeholders’ use
- Educate patients and families about CKD/ESKD and their
rights/options in all aspects of treatment
- Use World Kidney Day (WKD) to highlight education and
lobby governments
ISN advocacy portfolio, patient and parent
groups, kidney foundations, national and
regional nephrology societies, medical
communities, organ donor initiatives
- Key messages, infographics, eco-
nomic analyses, case studies
- Established community groups
with medical staff and families to
drive treatment action campaign
- Annual WKD events
Develop country-speciﬁc patient engagement strategies
- Conduct consumer engagement workshops in each
country to:
 Identify, promote, and implement effective commu-
nity involvement strategies in registries
 Advise strategies for converting epidemiology infor-
mation into patient-centered information
 Determine patient-relevant clinical priorities in ESKD
care
 Determine research priorities in ESKD
 Deﬁne barriers to ESKD care
 Deﬁne enablers of ESKD care
 Establish patient ESKD advisory group in each
country
Patient and parent organizations, ISN and
other national and regional professional
associations, local and national health
service providers and funders, industry,
governments, NGOs
- Annual report detailing consumer
engagement workshops held
- Register of patient ESKD advisory
groups established in each
country
CKD, chronic kidney disease; ESKD, end-stage kidney disease; ISN, International Society of Nephrology; LMICs, lower-middle–income countries; NGOs, nongovernment or-
ganizations; WHO, World Health Organization.
DCH Harris et al.: Global access to ESKD care I SN pub l i c a f f a i r sDecision makers in LMICs would beneﬁt from a tool that
describes and justiﬁes the principles behind establishing a
national kidney care program, including the 2 forms of evi-
dence summarized above. This tool should present the 4
principles (in Table 5), and identify the preparatory work that
countries must do before applying the principles (e.g., assess
burden of kidney disease and ESKD, identify existing human
capacity and relevant infrastructure, and consider and agree
on health policy priorities). The tool should also make
explicit the above-mentioned factors that may prevent a
country from developing kidney care services in the order
implied by the 4 principles, as well as suggesting metrics that
help to inform countries when offering a more sophisticated
kidney care program (e.g., what proportion of the population
should have reasonable access to preventive services and
supportive care before a kidney transplantation program is
implemented, developing equitable and transparent rationing
policies for access to dialysis). Care needs to be taken to
ensure that supportive and/or palliative care is seen as an
essential, integral component of comprehensive ESKD care, as
it is with oncology and AIDS care. Priorities for spending on
KRT programs need to be agreed upon by patient groups, the
public, health care professionals, and policy makers.
Support stakeholders in advocating for integrated kidney care
programs within their countries. From an advocacy perspec-
tive, current global efforts to establish UHC and the focus on
NCDs are useful opportunities in making a case for change in
kidney care.47 In this context, there is a speciﬁc opportunityKidney International (2019) 95, S1–S33to set out what an essential package of health services might
look like for kidney care under UHC—and to emphasize that
treatments for preventing and managing will often help to
prevent and treat other NCDs such as diabetes and vascular
disease. In such a fully integrated, people-centered health
system, people with ESKD need the education and support to
choose from the range of available care modalities—optimally
HD, PD, transplantation, and comprehensive conservative
care—and have their health-related quality of life (HRQoL)
and well-being optimized on that modality. Potential stake-
holders in this objective include health facilities, patient or-
ganizations, and national and/or regional nephrology
societies. These stakeholders would beneﬁt from tool kits and
education that support them to advocate for rational kidney
care programs. The tools would need to acknowledge and
respond to the highly variable contexts, health systems, and
large number of stakeholders that are involved within
and across the different LMIC audiences.
It would be critical to ensure that these advocacy tools are
aligned with the messaging for decision makers (above), as
well as with the messaging in other relevant documents from
key stakeholders such as ISN, Kidney Disease: Improving
Global Outcome (KDIGO),40 WHO and the HEARTS tech-
nical guidance initiative.7
Develop country-speciﬁc patient engagement strat-
egies. Adults and children with advanced CKD experience
high symptom burden and have complex health and social
care needs.48–51 Involvement of patients and caregivers isS9
Table 5 | Principles of establishing a comprehensive kidney
care program
1. Interventions to slow or prevent progression of kidney disease to ESKD
are effective, are highly cost-efﬁcient, have synergies for the prevention
and management of diabetes and vascular disease, and are easily
integrated with other programs aimed at NCD prevention and control.
Such preventive care should be the highest priority for kidney care
programs in LMICs.
2. Supportive care and comprehensive conservative care programs should
be established in parallel with preventive care programs. For LMICs,
there is a need to agree on an essential package of resources and in-
terventions for people with CKD and ESKD required to minimize the
burden of serious (kidney) health-related suffering.
3. Among KRT modalities, kidney transplantation in suitable patients is
associated with the best clinical outcomes at the lowest cost.
4. PD is associated with outcomes that are similar to those for HD. For
LMICs that are contemplating chronic dialysis programs, whether PD
should be prioritized over HD or free choice is allowed should be based
on cost evaluation. Local manufacture of PD solutions may help to
realize the potential economic beneﬁts of PD.
CKD, chronic kidney disease; ESKD, end-stage kidney disease; HD, hemodialysis; KRT,
kidney replacement therapy; LMICs, lower-middle–income countries; NCD, non-
communicable disease; PD, peritoneal dialysis.
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD carecritically important to ensuring that planning of ESKD care,
within the overall context of health care, meets consumer
need and is appropriately prioritized. Patient involvement in
research priority setting is increasing in frequency but still
relatively rare,52 and it is not currently known to what extent
patients participate in, and inﬂuence, ESKD care planning in
different countries around the world. This knowledge gap
could be addressed through surveys and gray literature review,
supplemented by qualitative research in patients and care-
givers to identify barriers and enablers of ESKD care in
different countries. Patient involvement, such as in the CAN-
SOLVE-CKD Network,53 would also help to improveTable 6 | Suggested pathways and strategies for developing inte
Pathways Partners
Understand ESKD burden at
national and local level
National health administr
National nephrology soc
CKD or ESKD committee at national
or nephrology society level
National health administr
National nephrology society Nephr
leadership
Patient organizations
Standardization for integrated CKD
and ESKD care
National health administr
National nephrology soc
International societies (ISN, regional
etc.)
Implementation of integrated CKD
and ESKD care system
Primary and secondary care p
Multidisciplinary health care
Patient organizations
Sustainability and quality
improvement
National health administr
Social scientists, health economi
Outcome measures National health administr
National nephrology soc
CKD, chronic kidney disease; ESKD, end-stage kidney disease; ISN, International Society
S10transparency in different countries regarding criteria for pa-
tient access to KRT. Additionally, initiatives such as Stand-
ardised Outcomes in Nephrology (SONG) have involved
patients as important stakeholders in the deﬁnition of rele-
vant clinical outcomes for research purposes in ESKD.54
In relation to transplantation, patient involvement can
help build community support for deceased organ donation
and promote transparency in allocation of kidneys and
acceptance of patients onto waiting lists. Closely aligned with
this is community engagement and education. Promoting the
community’s understanding of the concepts of death deter-
mination and the beneﬁts of organ donation will be a beneﬁt
to society. In many societies, it would be essential to involve
local religious, traditional, and cultural leaders in the devel-
opment of patient education and awareness programs.
Theme 3: education and training/workforce. Develop locally
appropriate strategies to enhance health workforce capacity
As stated in theme 1, there are important gaps in the orga-
nization, knowledge, and practice of the health care workforce
in ESKD care around the world—from the standpoint of
physicians, nurses, and technicians. This is particularly true in
LMICs, where there is often a lack of adequate education and
training programs and funding. Adequate care for patients
with ESKD (dialysis, transplantation, and conservative care) is
not possible without a sufﬁciently trained and appropriately
distributed workforce.55 Activities to evaluate and enhance
the nephrology workforce are discussed below and summa-
rized in Table 7.
Evaluate workforce and its training. If sustainable ESKD
care programs are to be developed, an initial, important ﬁrst
step is to collect accurate information about the number,grated CKD and ESKD care
Actions
ation
iety
CKD/ESKD registry
Epidemiology studies
Risk factor identiﬁcation
Target population deﬁnition
ation
ologist as core
CKD prevention program
Multidisciplinary care program
Replacement therapy quality control
Renal transplantation promotion
ation
iety
societies, WHO,
CKD guideline
Dialysis guideline
Transplantation guideline
hysicians
teams
Multidisciplinary and multi-professional care
approaches
ation
sts, industry
Funding assurance and health care coverage, bulk-
buying dialysis supplies and immunosuppressive
therapy
ation
iety
Annual report and outcome assessment
of Nephrology; WHO, World Health Organization.
Kidney International (2019) 95, S1–S33
Table 7 | Strategies to evaluate and expand the health workforce capacity for sustainable ESKD care programs to develop
Activities Partners Deliverables
Evaluate workforce and its training
- Develop robust methodology to collect data,
monitor, and make accurate renal workforce
projections
ISN, ISPD, IPNA, national and regional
professional associations, local and national
health service providers, dialysis providers,
academic centers, health ministries
- Report and needs assessment detailing
available resources, barriers, facilitators,
and projection of future needs
- Evaluate the following:
 Training, education, and knowledge
of physicians, nurses, and technicians
 How existing national training programs
and training provided by international
organizations and academic centers
contribute to expanding the workforce
 Training models and the impact of
accreditation; include models applied by
other NCDs (e.g., AIDS, oncology, diabetes,
and hypertension)
ISN, ISPD, IPNA, WHO, academic centers,
national and regional associations and
societies, CME organizations, dialysis
provides, national health programs, health
ministries
- Guidelines for the education and training
of adequate ESKD care workforce
- Recommendations on the following:
 How the international community can
best help with training programs in
LMICs
 How education of the workforce can
best be organized and coordinated
 Training lessons learned from other
programs
 Practicability of implementing an
accreditation program
Develop strategies to enhance health workforce capacity
- Explore use and effectiveness of newer
technologies to enhance training and care
including telemedicine, online and
web-based education, and training tools
- Develop and evaluate effectiveness
of regional networks for support, training,
and continuing education
International, national, and regional
professional associations, local and national
health service providers and funders,
industry, governments, NGOs, ISN and other
national or regional nephrology societies,
academic centers
- A resource hub with tools that can be
adopted or adapted by national
organizations
- Online public health training in
nephrology
- Promote ISN and other professional
organization fellowships and training
Academic Centres, ISN and other international,
national, and regional professional
associations and societies, local and national
health service providers and funders,
industry, governments, NGOs
- Increased participation in nephrology
fellowships and training
- Encourage PPP or PPI to support training
with appropriate oversight ensuring that the
right targets and messages are conveyed
- Private or philanthropic support of
training
Facilitate ESKD care-speciﬁc training to increase nephrology workforce
For PD and HD:
Prepare speciﬁc skill sets for the delivery of
dialysis utilizing various personnel including
nephrologists, primary care physicians,
nurses, and technicians
Professional nursing and technician
organizations, national medical societies,
academic centers, training centers, dialysis
facilities, telemedicine
- A resource hub with tools that can be
adopted or adapted by national
organizations
For transplantation:
Develop handbook of requirements for
transplant centers including transplant
evaluations and longitudinal care after
transplantation
ISN-TTS sister transplant programs and
tripartite relationships, local professional
societies and colleges, ASHI
- Established expertise in laboratory medi-
cine and tissue typing
- Trained staff to address all requirements
for a successful transplant program
For conservative and supportive care:
Develop training in symptom assessment,
communication skills, advance care
planning, supportive care, and use of
prognostic models
Experts in communication skills training, multi-
professional experts in supportive care,
advance care planning and palliative care,
ISN and other national and regional
professional associations, patient and parent
organizations, online resources for patients
with ESKD and providers, existing academic-
ministry partnerships
- A resource hub with tools that can
be adopted or adapted by national
organizations
ASHI, American Society for Histocompatibility and Immunogenetics; CME, continuing medical education; ESKD, end-stage kidney disease; HD, hemodialysis; IPNA, International
Paediatric Nephrology Association; ISN, International Society of Nephrology; ISN-TTS, International Society of Nephrology - The Transplant Society; ISPD, International Society
for Peritoneal Dialysis; LMICs, lower-middle–income countries; NCDs, noncommunicable diseases; NGOs, nongovernmental organizations; PD, peritoneal dialysis; PPI, public-
private investment; PPP, public-private partnerships; WHO, World Health Organization.
DCH Harris et al.: Global access to ESKD care I SN pub l i c a f f a i r scompetence, knowledge, and distribution of the existing
workforce. The second step is to evaluate the available edu-
cation and training programs and perform a needs assessment
by identifying the barriers and facilitating factors that would
inform development of appropriate training modules to
provide and augment the basic and ongoing education of the
workforce. The third step is to estimate the workforce and
educational needs to support the expansion of ESKD care
services. Learning from the experience of other specialties inKidney International (2019) 95, S1–S33providing creative workforce and educational models should
be explored. It is essential to focus attention not just on the
nephrologists, but on primary care physicians and nonphy-
sician workers, such as nurses, technicians, nutritionists, and
social workers.56–58 Because LMICs generally have limited
personnel to provide ESKD care, nurses (registered and
practical), technicians, and all-purpose assistants can be
recruited and trained.59,60 Similarly, limited availability of
nephrologists requires engaging primary care physicians andS11
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD caregeneral surgeons for management of various aspects of ESKD
care. Special mention should be made of the need of health
care workers to manage children with ESKD.
International education and training programs, available
through international organizations and global health pro-
grams of universities of other countries, can be helpful. While
training in the local environment is ideal, organizations like
ISN, International Society for Peritoneal Dialysis (ISPD),
International Paediatric Nephrology Association (IPNA), and
the Transplantation Society (TTS) have supported nephrol-
ogist and specialist training through their programs that
permit those from LMICs to travel to training programs in
HICs for varying durations (see Supplementary Table S3).
Despite the risk of “brain drain,” recent data from these or-
ganizations indicate that the vast majority of trainees from
LMICs who receive training in HICs return to their country
of origin.61 However, unless it is targeted to speciﬁc needs,
training in HICs may not lead to accrual of knowledge rele-
vant for practice and needs in LMICs. Short training periods
focused on speciﬁc aspects of ESKD care, particularly
involving hands-on care, can be useful. For example, focused
hands-on training for both nurses and physicians to learn the
basic principles of PD, techniques of PD catheter placement,
and/or training algorithms for PD have been accomplished
with short-term grants for physicians and nurses from LMICs
visiting well-established dialysis centers.62
Develop strategies to enhance health workforce capaci-
ty. Exploring the use of newer technologies to enhance
training is essential. Telemedicine health support systems,
web-based education programs, webinars, ready availability of
international guidelines with adaptation tools, web posting of
a wide variety of educational materials (e.g., on ISN Academy:
https://www.theisn.org/education-external/isn-academy), and
online consultations and support can all help to support the
education of personnel involved in ESKD care.63,64 Examples
of such programs include some of the educational initiatives
instituted by the ISN, ISPD, and SLANH utilizing web-based
education programs.
Renal workforce shortages are exceedingly common,
particularly in LICs. For example, nephrologist densities vary
over 1000-fold across the globe, averaging 0.32 pmp in LICs
and 28.52 pmp in HICs.13,14 Expanding the roles of available
workforce could permit rapid expansion of ESKD care. Well-
trained technicians, with appropriate education and super-
vision, could undertake many of the duties related to dialysis
care.65 For example, the expansion of PD in some HICs has
been assisted by the use of technicians to provide support for
patients at home (so-called assisted PD). Furthermore, pri-
mary care health workers with appropriate training can play
an important role in the basic management of ESKD (S.
Antwi, unpublished data).
The development of regional and local training programs
focusing on locally relevant skills has the potential to increase
access to, and improve the quality of, ESKD care. For
example, the Red Cross War Memorial Children’s Hospital in
Cape Town, South Africa, has created a “kidney program”S12that trains teams of doctors and nurses in hands-on skills to
manage patients with acute kidney injury (AKI) in an
intensive 1-week course, trains pediatricians from Africa for 1
and 2 years in nephrology, and trains adult nephrology fellows
in pediatrics for 1 month. It is hoped that the latter will allow
the trainees to at least address the basics of kidney disease in
children upon their return to their local sites. The East Af-
rican Renal Institute has recently been established in Nairobi
to help train nephrology fellows from the region. The African
Population and Health Research Centre (APHRC) in Kenya is
working to encourage research into local issues in Africa,
including a focus on chronic disease management.66 The
center has made it possible for doctoral training at African
universities via the Consortium for Advanced Research
Training in Africa (CARTA).61 Regional training networks
need to be developed for support, training, and continuing
education of the ESKD workforce.
The importance of the involvement of dialysis facility pro-
viders in supporting the education of technicians, nurses, and
physicians needs to be emphasized. This is the case whether the
facility is developed by the government, hospital, physicians, or
public-private partnerships (PPP) or investments (PPI). There
needs to be assurances that this training conforms to interna-
tional standards. Appropriate oversight of such training,
therefore, needs to be organized based on approved criteria,
such as those developed by the Board of Nephrology Examiners
Nursing Technology (BONENT) in the USA and used in other
countries such as India.
Facilitate ESKD care-speciﬁc training to increase nephrology
workforce. Adequate education and training of the work-
force requires that speciﬁc skill sets to cover all dimensions of
ESKD care be deﬁned. For example, for HD, training needs
include concentrate chemistry, accurate weighing of patients,
volume control, infection control, indications for vaccination
of patients and staff, indications for patient isolation, risks
and beneﬁts of dialyzer reuse, and responses to intradialytic
complications. For PD, speciﬁc educational dimensions that
need to be addressed include the kinetics of PD, how the PD
prescription is determined, how to deal with catheter in-
fections and mechanical problems, how to manage other
dialysis-related infections, and when to transfer patients to
HD. Dietitians and social workers are often not part of the
health care team for dialysis patients in LMICs. Dietitians
should be trained through local institutions, and when not
available, nephrologists, nurses, primary care physicians, and
technicians should be educated to discuss nutrition issues
with patients.
Transplantation is a highly skilled, multidisciplinary pro-
cedure and requires a specialized workforce with the appro-
priate qualiﬁcations. In addition to transplant surgeons and
nephrologists skilled at managing transplant patients, it re-
quires anesthetists, nurses, pharmacists, histopathologists,
laboratory technicians, and scientists to run a human tissue–
typing laboratory and dialysis backup. Training in supportive
and conservative care is often lacking, even in HICs. Clinician
(nurse, physician, and allied health personnel) training inKidney International (2019) 95, S1–S33
DCH Harris et al.: Global access to ESKD care I SN pub l i c a f f a i r ssymptom assessment, communication skills, advance care
planning, supportive care, and the use of prognostic models
needs to be developed. Of particular importance is additional
training of those caring for children and young people in
LMICs, where ESKD care options are limited.
Theme 4: ﬁnancing/funding models. Develop ﬁnancial
strategies and funding models to ensure equitable integrated
ESKD care
There is compelling evidence to show that the availability,
reach, and quality of ESKD care are directly linked to the
wealth of a country and the proportion of resources spent on
health care.27 In a recent survey designed by ISN to collect
information related to KRT in LICs and LMICs, government-
funded KRT was associated with higher access to dialysis and
transplantation, when compared with self-funded out-of-
pocket (OOP) models of reimbursement (unpublished
observation from the ISN Kidney Collection: https://www.
theisn.org/news/item/3282-presenting-the-kidney-collection-
survey). Therefore, development of locally appropriate
ﬁnancing models is key to establishing sustainable KRT
programs throughout the world.
In afﬂuent countries, dialysis is generally available to
everyone who has the potential to beneﬁt from it. On the
other hand, as an expensive and cost-inefﬁcient public health
intervention, dialysis has been rated by the WHO to be a low
priority for governments with limited resources.67 Despite
this, as documented by the GKHA,13,14 HD is currently
available in all countries of the world, including those that are
unable to ﬁnance even basic health care services. Public
funding for dialysis is available in 71% of countries, including
73% of LMICs and 44% of LICs.14 Free dialysis at the point of
care is available to some proportion of the population in 63%
of countries.14 However, the extent of the coverage is widely
variable. An increasing number of countries are including
coverage of dialysis in their UHC agenda under the sustain-
able development goals.
The decision to provide public funding for KRT is often
driven by political rather than medical or economic factors,
and is inﬂuenced by the perceived need and requirements of
societies based on inputs from stakeholders in the overall
context of values, human rights, equity, and self-
determination by governments.68 Each country selects an
acceptable amount of KRT funding as a proportion of the
overall health care budget. Given that chronic dialysis is so
costly, universal coverage is not sustainable for most LMICs.
Therefore, locally acceptable rationing criteria with trans-
parent methods for their application need to be developed
alongside sustainable funding models.69,70
Two general principles related to ﬁnancing of health
care71,72 can be applied to dialysis: efﬁciency (optimal use of
resources to minimize avoidable losses) and progressivity
(making the service available in an equitable manner to the
rich and the poor, such that those with unequal ability to pay
do pay differentially). The latter is directly linked to UHC,Kidney International (2019) 95, S1–S33which stipulates that people should be able to access dialysis
without risking ﬁnancial ruin or impoverishment. In practice,
however, there are signiﬁcant departures from these principles
in both HICs and LMICs. In particular, within many LMICs,
salaried workers in the private and government sectors, as
well as wealthy patients, are able to access dialysis that is not
available to the rest of the population.73,74
Evidence of efﬁciency should come from health technology
assessment (HTA), which evaluates the clinical effectiveness
and cost-effectiveness of available ESKD treatment alterna-
tives (HD, PD, transplant, and conservative care). Acting as
a bridge between evidence and policy-making, HTA helps
in efﬁcient allocation of resources and discourages use of
interventions whose cost is too high compared with
beneﬁts.75–78
PD is often promoted where dialysis is primarily funded by
the government. For example, the government of Thailand
conducted an HTA and determined that PD was the more
cost-effective option while providing acceptable level of
clinical effectiveness.20,78,79 This prompted the adoption of a
“PD-ﬁrst” policy in which all eligible patients are offered PD,
with the more expensive HD restricted only to those with a
medical indication, or those with private insurance. Similar
policies operate in Hong Kong. Other countries (Mexico,
Guatemala, Canada, Spain, China, and Taiwan) have adopted
a less strict “PD-preferred” policy.80 In some LICs, however,
the delivery of PD is expensive46 because of the need to
import supplies, the imposition of additional taxes and duties,
and transportation costs. Finally, lack of well-designed health
economic studies from a health system or societal perspective
has prevented accurate cost determinations of competing
KRT options in LMICs, leading to unfounded assumptions.
For example, a recent study from India81 showed that when
the complete economic health system costs of HD including
personnel salaries, capital infrastructure (building and
equipment), and basic medical supplies were estimated, the
cost to the system was found to be 4 to 8 times higher than
estimated previous reports. This makes HD far more expen-
sive than PD, contrary to the currently accepted narrative that
PD is more expensive than HD in India.
Despite the superiority of transplantation for suitable
subjects in terms of cost-effectiveness as well as clinical ben-
eﬁts, public ﬁnancing of transplantation is not uniformly
provided in LMICs. According to GKHA, public funding for
transplantation was available in only 25% of LICs and 52% of
LMICs.13 This creates an anomaly in which a patient may
choose to receive dialysis rather than a transplant just because
the former is free at the point of care, whereas patients have to
pay out-of-pocket for immunosuppressive drugs. Similarly,
conservative care rather than dialysis may be more appropriate
for certain patients11 but is not supported by public funding
because it is not perceived as a form of active care, but rather
an admission of defeat. Activities to develop ﬁnancial strategies
and funding models to ensure equitable integrated ESKD care
are discussed below and summarized in Table 8.S13
Table 8 | Develop ﬁnancial strategies and funding models to ensure equitable integrated ESKD care
Activities Partners Deliverables
Health care ﬁnancing models and their applicability to KRT
- Detail country-speciﬁc ESKD health care ﬁnancing
activities
- Reﬁne GKHA instrument to assess affordability,
accessibility, and quality of ESKD care within
and between countries
- Augment GKHA data with expanded survey
and gray literature review
Patient and parent organizations, ISN and
other national and regional professional
associations, local and national health
service providers and funders, industry,
health care policymakers, experts in
health economics
- GKHA special report
- Systematic review of published and
gray literature
- Revise original documents included in the
ISN collection and extract data on ﬁnancing
- ISN collection data extract on ﬁnancing
in LMICs
Compare impact of different models of provision and funding including public-private partnerships
Evaluate different ESKD care delivery models. Examine
approaches to:
 Marketing
 Tailoring services to the poor
 Strategic purchasing
 Lowering operating costs
 Cross-subsidization
 Optimizing human resources product and process
reengineering
 Increasing outreach
 Information management
 Integration and system stewardship
ISN, ISN regional boards, national societies,
health economists, process evaluation
experts, large dialysis providers
- Case studies describing complete marketing,
ﬁnance, and operations solutions
- Identiﬁed opportunities for disruptive
business process innovation
(A) Impact on equity
Survey of all countries regarding their current model
in terms of funding and provision of care
ISN GKHA, WHO, WHO’s regional ofﬁces,
national and regional nephrology
societies
Thematic summary of different models
(B) Impact on outcomes
Determine the outcomes of these different models in
terms of hard endpoints
ISN GKHA, WHO, WHO’s regional ofﬁces,
national and regional nephrology
societies, USRDS, ERA-EDTA
Description of impact in terms of:
- Incidence and prevalence of HD, PD, TX,
non-KRT initiatives
- Demographics of those receiving or not
receiving care
- Survival and mortality
- Percentage of health care budget and of GDP
being spent on ESKD care
Advocate for universal access to essential drugs and dialysis components for patients with ESKD
- Review existing guidelines and care packages ISN, WHO, MOH, patient organizations,
industry, KDIGO and other guideline-
producing bodies
- Best practice recommendations for dialysis
practice and affordable treatment of medical
problems in patients with ESKD
- Review drugs included in WHO strategic fund - Essential drug list, including
immunosuppressive drugs for
transplantation
- Request WHO assistance in dealing with countries
applying high fees or import duties on PD supplies
- Strategic purchasing guidelines
Economic and societal return on investment
Evaluate cost-effectiveness in different settings: PD
versus HD versus TX versus conservative care
MOH, health economists, process analysts,
nephrologists, industry
- Simulator tool or paper
- Tools to calculate the differential costings
between HD, PD, and transplantation that
are region-speciﬁc and relevant for LMICs
and HICs
Measure beneﬁts to society: jobs created, skills, trade,
knowledge generated, economic returns to society
through better rehabilitation of patients
Health economists, process analysts,
nephrologists, social scientists
- Position paper
- Tools to track returns on investment beyond
deaths and DALYs
Develop narrative case study of countries where the
approach changed at some point in time, and how
that impacted outcomes
Speciﬁc participants - Thematic summary of different models
DALYs, disability-adjusted life years; ERA-EDTA, European Renal Association-European Dialysis and Transplant Association; ESKD, end-stage kidney disease; GDP, gross do-
mestic product; GKHA, Global Kidney Health Atlas; HD, hemodialysis; ISN, International Society of Nephrology; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney
replacement therapy; LMICs, lower-middle–income countries; MOH, Ministry of Health; PD, peritoneal dialysis; TX, transplantation; USRDS, The United States Renal Data System;
WHO, World Health Organization.
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD careHealth care ﬁnancing models and their applicability to
KRT. Health care ﬁnancing models can be tax-based, insur-
ance-based (social or private), or as OOP payments.83 All 3
models are used to fund dialysis, with the ﬁrst one being mostS14prevalent throughout wealthy countries. Even in countries
such as the US, where general health care ﬁnancing is done
through insurance, dialysis is unique in being funded by
general revenue. On the other hand, OOP is the mostKidney International (2019) 95, S1–S33
DCH Harris et al.: Global access to ESKD care I SN pub l i c a f f a i r scommon model of ﬁnancing for dialysis in LMICs, which can
lead to catastrophic health care expenditure and distress
ﬁnancing.81,82 The model of funding and organization im-
pacts on equity, irrespective of the budget available. For
example, Colombia, with a gross domestic product per per-
son (GDPc) of US $7500, has a public health expenditure of
4.5% of GDP, whereas Mexico, with a GDPc over US $10,000,
spends only 3% of GDP on health, resulting in OOP expen-
ditures of 25% and 50%, respectively.83–85 However,
Colombia has universal access to KRT, whereas Mexico does
not. In India, even short periods of dialysis while awaiting
kidney transplantation in a public-sector hospital caused
catastrophic health care expenditure in over 80% of the
population.82
Financing choices affect both efﬁciency and progressivity.
Optimal design of dialysis ﬁnancing cannot be isolated from
the rest of health care in a welfare state, however. Even when
providing dialysis to the poor from public funds is prioritized
in principle, it has proven to be difﬁcult to implement in
practice. Experience from some jurisdictions that have
introduced state-funded dialysis shows that other compo-
nents of dialysis delivery that result in OOP expenditures (no
matter how small their contribution) culminate in cata-
strophic health care expenditure and premature withdrawal
from dialysis, thereby preventing attainment of equity.86
Recognizing the need for reform, the government of the
state of Andhra Pradesh in India provides a monthly grant of
INR 2500 (US $35) through direct cash transfer to offset OOP
expenses incurred on dialysis.87 Many countries have several
different reimbursement schemes to fund KRT, which also
diminish progressivity and perpetuate inequities in access to
and outcomes of KRT.
Disparate ﬁnancing models also create perverse incentives.
For example, in some systems, nephrologists are paid per HD
session, and hence stand to earn more from this modality,
leading to disincentivizing of other KRT modalities. Prefer-
ential referral by nephrologists to HD units in which they
have a ﬁnancial stake constitutes additional ﬁnancial con-
ﬂict.69 In view of this, many countries that fund dialysis
through tax revenues have made nephrologist reimbursement
uniform for both forms of dialysis.
Anecdotal reports have described informal insurance
mechanisms such as charity, informal credit, and micro-
ﬁnancing for funding KRT.88 While they reduce some of the
ﬁnancial burdens, they may not fully address all of these costs,
and might add to inequity. The policy implications of such
informal mechanisms for funding ESKD care need to be
clearly understood.
Additional barriers are faced by some populations that are
culturally deprioritized in some societies, such as women,
children, and the elderly. Medical care for the primary
breadwinners (usually men) is prioritized when there is a cap
to the coverage amount. In a state-funded dialysis scheme in
India, the female-to-male ratio was 1:3.5.86
Countries that have committed to supporting broad-based
dialysis programs are likely to experience increase in demandKidney International (2019) 95, S1–S33as the ﬁnancial barrier is removed, which will force identiﬁ-
cation of new revenue sources (taxes), or disinvestment in
other services. Alongside ﬁnancing issues, governance and
organizational factors need to be taken into account to
optimize equitable use of limited resources when providing
expensive ESKD care.21
The biennial GKHA surveys13,14 should be reﬁned to
evaluate affordability, accessibility, and quality of ESKD care
within and between countries. This information should be
supplemented by a comprehensive review of published and
gray literature. Data pertaining to ESKD care ﬁnancing in
LMICs can be extracted from the ISN Kidney Collection
(https://www.theisn.org/news/item/3282-presenting-the-kid-
ney-collection-survey).
Compare impact of different models of provision and funding:
public-private partnerships. Governments may enter into
agreements with the private sector to ﬁnance, build, and
operate dialysis units for an agreed-upon return on invest-
ment. The rationale for using public-private partnerships
(PPPs) emerges from the gaps in dialysis delivery and private
investment in areas where there are limited public providers.
Many LMICs that are developing dialysis as part of their UHC
agenda are doing so through PPPs. PPP offers innovation
opportunities, such as implementation of uniform protocols
across a large number of units, reduced costs through stra-
tegic purchasing, better outcomes and service quality tracking
through information technology services, and tying service
delivery with requirements for workforce capacity-building
and ancillary programs. For example, the PPP model in
Colombia has been tied to promotion of kidney health, CKD
prevention, free choice of KRT, and mandatory reporting.89
Examples of PPP programs are to be found in India,90
Russia,91 Mexico,92 and Swaziland.
While PPPs have permitted ESKD care services to
expand,86 there are few studies that have evaluated their
ability to deliver efﬁciency gains in countries where access and
equity are major concerns. The function of PPPs in LMICs
can be further hampered by lack of strong governance and
monitoring mechanisms, misbehavior of market forces,
contract disputes, and lack of dispute resolution mechanisms.
Further, the contractual workforce in PPPs may face lower
pay and poor working conditions.93 In some regions, PPP
resulted in a decrease in PD utilization, with a signiﬁcant
increase in total dialysis expenditure.74,92,94 We need more
data on the performance of PPPs in dialysis delivery in
different countries.
Advocate for universal access to essential drugs and dialysis
components for patients with ESKD. While developing
ﬁnancing strategies for KRT, many countries omit coverage
for ancillary medical needs.86 As a result, patients end up
incurring OOP medical expenses (antihypertensive medi-
cines, erythropoiesis-stimulating agents for dialysis, vaccina-
tions against hepatitis B virus, and immunosuppressive drugs
for transplant), dialysis access procedures, and additional
hospitalizations. A holistic approach to universal coverage of
drug treatment and comprehensive patient care is required.S15
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD careUse of generic medicines and development of strategic central
purchasing policies have the potential to reduce costs.
Economic and societal return on investment. The eco-
nomic and societal return on investment in ESKD care can
also be measured in terms of monies saved when the most
appropriate KRT model was implemented, jobs created
(both for health care professionals and for patients), and
skills, trade, and knowledge generated that can be leveraged
to increase equitable access to health care. In terms of so-
cietal returns, part of the costs of ESKD care ﬂow back to
the community as they pay for nurses and technicians and
allow ESKD patients to remain economically productive.
This approach also allows development of tools to measure
return on investment in economic terms, rather than
only deaths and disability-adjusted life years (DALYs)
averted.
As emphasized in themes 1 and 3, ESKD funding systems
should allocate resources toward registries and workforce
training. Finally, any responsible model to fund KRTmust be
coupled with population-based programs to detect early
stages of CKD so that evidence-based public health in-
terventions can be implemented to prevent or retard the
progression to ESKD.4 Such an approach has been adopted in
many countries and is leading to either an arrest or even
decline27,88 in the incidence of new patients with ESKD.
Theme 5: ethics. Enunciate ethical principles surrounding
ESKD care
Ethical challenges in ESKD care are encountered at all levels
from policy development and administration to clinical
practice. Questions at the policy level such as prioritization of
CKD prevention versus treatment of advanced disease, equi-
table access to care for those with ESKD, rationing of re-
sources (e.g., dialysis and transplantation), and decisions to
initiate or continue KRT are relevant in all countries, but are
especially challenging in LMICs21,95,96 (see theme 2). For
clinicians, decisions regarding starting and/or continuing
dialysis may present multiple ethical dilemmas.97 Many pa-
tients, especially the elderly, have multiple comorbidities and
psychosocial complexities that complicate the qualitative
assessment of potential treatment beneﬁts. Decision-making
is further complicated by diverse spiritual, cultural, reli-
gious, and socioeconomic backgrounds. In LMICs, the ethical
complexity of bedside decision-making about ESKD is exac-
erbated by constraints in availability of treatment, ﬁnancing of
care, quality of treatment delivered, as well as corruption in
some settings, leading to moral distress among patients,
families, and health care workers.21
Despite early work on the ethics of dialysis,98 ethics has
been a neglected discipline in nephrology with the exception
of kidney transplantation, which remains a popular topic for
inter-professional research, commentary, and guideline
development99 (see theme 7). Limited ethical analysis and
guidance relating to provision of integrated KRT, including
dialysis, means that there are multiple gaps relating to the
ethics of ESKD care.21,69,100S16Work is needed to ensure a considered approach to the
planning and delivery of ESKD care, to provide information
and expert opinion to assist policy makers in deliberations
concerning fairness in priority setting and resource allocation;
and to promote shared and informed decision-making about
management of kidney failure and provision of KRT in the
context of health systems—including provision of appro-
priate supportive care for all patients, whether or not they
receive dialysis.70,101–103 Sensitivity to global diversity in cul-
ture; consideration for special groups such as the under-
served, indigenous populations, migrants and refugees;104 and
use of reliable evidence of kidney disease burden and capacity
of health systems are imperative to inform ethical decision-
making.105
Evaluating practical issues identiﬁed above through an
ethical lens is necessary to inform development of ethical
frameworks to support decision-making, and to ensure that
practical solutions are consistent with the values and prefer-
ences of the communities they are intended to beneﬁt, as well
as those responsible for their implementation. Exploration of
the ethical aspects of ESKD care should build on past and
current ethics work, not only in nephrology, but also in the
context of public health, critical care, chronic disease man-
agement, and transplantation (Figure 4). Activities to enun-
ciate ethical principles surrounding ESKD care are discussed
below and summarized in Table 9.
Develop an international professional statement articulating
core ethical principles and values to guide policy and practice in
ESKD care. Speciﬁc ethical dilemmas relating to provision of
ESKD care require elaboration at the local level or in the
context of speciﬁc issues under the framework provided by
the overarching principles and values regardless of diversities
in environments. Health is a globally valued good, as is the
right to be included in decision-making about matters con-
cerning individuals and communities. Together, they provide
the foundation for a common ethical framework to guide
policy and practice in ESKD care around the world.
The development and communication of an international
professional ethics statement addressing the spectrum of
ESKD care, such as service planning, choice of type of KRT,
and conservative care is needed to clarify the standards and
goals of the global community of kidney care professionals.
Such a statement would serve to inform development of local
policy and practice, highlighting the importance of addressing
equity concerns and optimization of access to kidney care in
the context of local standards of care.106,107 The availability of
ethical guidance should enhance and promote equity in the
quality of care for patients and their families, for example by
assisting health care workers to advocate with and on behalf
of patients and their families and communities. It could also
reduce moral distress for health care workers confronting
ethical issues in ESKD care, for example, when burdened with
the responsibility for making rationing decisions in the
absence of ethical or institutional guidance or when required
to implement policies or work under circumstances which
may be inconsistent with their own ethical values.21,108Kidney International (2019) 95, S1–S33
Figure 4 | The range of stakeholders involved in end-stage kidney disease (ESKD) care, highlighting the multipronged approach
required to promote awareness of ethical challenges and support ethical practice pertaining to ESKD care. HCWs, health care workers;
WHO, World Health Organization.
DCH Harris et al.: Global access to ESKD care I SN pub l i c a f f a i r sRaise awareness and understanding of ethical aspects of ESKD
care among health professionals. Moral distress among
health care workers can lead to demoralization, regret of
choice of profession, and feeling “burnt out,” and contribute
to brain drain from LMICs.108,109 Distress may come from a
lack of guidance for clinical practice regarding access to KRT,
limited or nonavailability of palliative and supportive care,
and having to deliver care inconsistent with one’s own values.
Examples include deciding whether or not a family bread-
winner should receive potentially lifesaving KRT because of
lack of health system or patient resources, or when patients
and/or families insist on likely futile KRT simply because it is
available. Physicians often feel powerless to advocate against
restrictions imposed by the system, and lack of awareness of
guidance110 regarding ethical withholding or withdrawal of
care may exacerbate moral distress.
In order to stimulate theoretical and applied work on the
ethics of ESKD care, and to promote ethical practice in the
delivery of ESKD care, health professionals must be able to
recognize, understand, and appreciate the importance of
ethical concerns that may arise in policy or practice, critically
evaluate policies and practices from an ethical perspective,
and contribute to actions aimed at addressing ethical con-
cerns. Tools to approach ethical aspects of ESKD care, facil-
itate working through and articulating moral dilemmas at the
bedside, and foster mutual support to reduce moral distress
should be included in education and training activities to
build skills and knowledge among the nephrology workforce.
Ethical challenges should be explored in professional forums
such as academic conferences and in academic publications,
so as to stimulate discussion and encourage engagement with
opportunities for collaboration.Kidney International (2019) 95, S1–S33Increase inter-professional research, discussions, and
interventions on ethical issues in ESKD care. Development of
effective and ethical solutions to the multidimensional chal-
lenges of providing appropriate ESKD care to all requires
interdisciplinary research. Determining the fairest way to
distribute treatment resources requires knowledge of the local
health economics relating to KRT, the health care system
infrastructure, population disease burdens, and community
values and preferences.111–113 Capacity building among re-
searchers in local contexts is a prerequisite to support relevant
and meaningful studies. Clinicians, researchers, ethicists, and
health administrators must engage with community stake-
holders, civil society, industry, policy makers, and those
involved in advocacy and care delivery for related commu-
nicable and noncommunicable diseases.114
The development of a strategic plan for research in the
ethics of ESKD care at international and national levels will
help to establish priorities for multinational and multidisci-
plinary collaborative research.115 This is particularly impor-
tant given the global shortage of ethicists currently working
on issues in nephrology and the limited ethics expertise
available in some countries. A strategic plan will also help to
inform research funding decisions by those seeking to invest
in the ethics of ESKD care, and to guide the development of
regional and national research activities.
Develop issues papers and guidelines addressing speciﬁc
ethical issues in ESKD care. As Jha and colleagues and others
have highlighted21,69,116 and the deliberations of ISN’s 2nd
Global Kidney Health Summit in 2018 have made evident,
several ethical issues in ESKD care require urgent attention.
In some countries, issues relating to end-of-life decision-
making may be most acute, whereas in others, especiallyS17
Table 9 | Enunciate ethical principles surrounding ESKD care
Activities Partners Deliverables
Develop an international professional statement articulating core ethical principles and values to guide policy and practice in ESKD care
- Develop statement with key stakeholders
- Promote on ISN website and in communication
materials
Consultations: WHO, patient groups,
stakeholders in ISN, ASN, ERA-EDTA, and
other nephrology societies, ethics
experts from HICs and LMICs
- International professional ethics statement
on ESKD care
- Publication in nephrology, ethics, global
health journals
Raise awareness and understanding of ethical aspects of ESKD care among health professionals
Develop educational activities and resources
relating to ethics of ESKD patient care
ISN members, professional associations
(nurses, technicians, dietitians, social
workers), bioethicists with an interest in
nephrology, WHO, educators
- Webinar(s)
- Workshop(s) or special seminar(s) at
nephrology conferences
- Slide decks
- Case library with ethical analysis for use
in teaching
Develop nephrology ethics and advocacy
leadership and mentorship program to increase
capacity:
- Identify potential partners, develop program,
determine budget and outcomes
- Implement and evaluate a pilot program
Universities with bioethics programs - Nephrology ethics and advocacy training
curriculum (clinical, research, HPSR)
- Pilot program
- Tools to measure and reduce moral distress
Develop manuscripts on each ethical principle
identiﬁed above with theory and discussion
from LMIC and HIC perspectives
Clinicians in LMICs and HICs, clinical
ethicists, public health ethicists
Publication in nephrology, ethics, global health
journals
Encourage publications addressing ethical issues
in ESKD care by increasing research and
promoting awareness of such issues in the
nephrology and bioethics communities
Nephrology societies, International
Association of Bioethics, biomedical
journals
Ethics page on the ISN website (under Advocacy)
for collation of resources and promotion of
opportunities for collaboration
Increase multidisciplinary research and interventions on ethical issues in ESKD care
- Survey ISN members and stakeholder groups to
identify common ethical issues and concerns
and priorities for research
- Develop a strategic plan for research in
the ethics of ESKD care
- Build capacity among local researchers across
disciplines
- Identify opportunities for funding of research in
this ﬁeld and develop funding applications
- Identify research themes and regional gaps to be
addressed by ISN nephrology ethics fellows
Philanthropists, WHO, national ethics
committees
- Descriptive international study evaluating
common ethical issues and priorities in ESKD
care
- Strategic plan for research in the ethics
of ESKD care
- Research training focus within ethics work-
shops at national and international meetings
and integrated into nephrology ethics
fellowships
Develop issue papers and guidelines addressing speciﬁc ethical issues in ESKD care
Form working group(s) to investigate speciﬁc
issues (informed by survey planned above) and
develop ethical guidelines for policy and/or
practice, including the issue of priority setting
and/or allocation of resources for ESKD care
Bioethicists, WHO, policy makers, national
societies, ISN regional boards, public
health ethicists
Publication of issues papers and guidelines
ASN, American Society of Nephrology; ERA/EDTA, European Renal Association – European Dialysis and Transplant Association; ESKD, end-stage kidney disease; HICs, high-
income countries; HPSR, Health Policy and Systems Research; ISN, International Society of Nephrology; LMICs, lower-middle–income countries; WHO, World Health
Organization.
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD carethose with limited health resources, issues relating to jus-
tice in the distribution of resources may be prioritized. In
addition, conﬂicts of interest—particularly ﬁnancial
ones—may inappropriately inﬂuence decision-making
about many aspects of ESKD care if they are unrecog-
nized and/or not managed appropriately.
The development and promulgation of papers exploring such
issues and review of existing guidelines providing recommen-
dations for ethical practice in ESKD and relevant conditions will
enhance awareness and improve the quality of care received by
patients and their families, reduce inconsistencies in policy and
practice, improve fairness and efﬁciency, and reduce anxiety and
distress that professionals, patients, and other decision-makers
may experience when grappling with ethical uncertainty orS18unethical practices. Highlighted here are examples of 2 priority
areas for more focused ethical work.
(i) Challenges in resource allocation are particularly acute
and ethically complex in resource-limited set-
tings.21,96,116,117 The provision of ESKD care should aim
to promote equity of access, such that criteria used to
allocate public funding for ESKD care, or to determine
eligibility for KRT, are primarily based on evidence-based
medical parameters, not socioeconomic status.118–120
However, in the absence of guidelines to govern
resource allocation, the ability to pay for care is often the
most inﬂuential, or the only, factor determining access to
care. The extent to which funding issues may justiﬁably
inﬂuence resource allocation decisions in provision ofKidney International (2019) 95, S1–S33
DCH Harris et al.: Global access to ESKD care I SN pub l i c a f f a i r sESKD care, if at all, is a topic deserving of substantial
further work.
(ii) While dialysis (or transplantation) may be life-saving, it
may also impose signiﬁcant burdens—economic, clinical,
and social—on patients and their families and has
important implications for the broader community.21,69
Thus, even when there are few resource constraints
directly inﬂuencing access to ESKD care, the potential
beneﬁts of various care modalities must be evaluated in
comparison with the potential burdens and considered in
the context of broader personal and societal goals.77,103
Determining who should be involved in making such
evaluations and how individuals or groups should be
involved in decision-making requires careful ethical
deliberation. Respect for autonomy is a widely accepted
ethical norm in the context of health care delivery.
However, operationalizing this may be complicated in
some sociocultural and health care environments, and in
the context of speciﬁc decision-making dilemmas.121,122
Theme 6: dialysis. Deﬁne, recommend, apply, and develop a
monitoring framework for minimum and optimal safety and
quality standards for peritoneal dialysis and hemodialysis
The quality of dialysis delivered to patients varies from country
to country, region to region, and facility to facility. This is
particularly so in countries without universal standards of care
and governmental (or other organizational) oversight,
including audits of quality of care. This can result in suboptimal
or poor quality of care.123 Oversight of dialysis care occurs in all
HICs, usually based on adherence to standardized, evidence-
based guidelines, tracking of outcome measures (e.g., mortal-
ity and hospitalizations), commercial oversight, and inputs of
regulatory organizations, such as health care commissioners,
insurance providers, and those dealing with technical speciﬁ-
cations for machines, dialyzers, water, and dialysate purity.
Many LMICs appear to have no or limited organized oversight
systems to ensure that safe and effective care is provided.
Guidelines for HD and PD have been produced for more
than 20 years in HICs. A wide range of guidelines have been
developed in Europe, Australia, USA, and Canada. Compre-
hensive PD guidelines have been published dating back to
1998 by ISPD.124 In addition to the national guidelines,
nephrology societies, government (both national and
regional) health departments, and dialysis facility owners have
developed guidelines to reduce practice heterogeneity and
improve quality and safety standards. The application of such
standards and guidelines in LMICs is uncertain since the
implementation of these guidelines generally assumes sufﬁ-
cient workforce and ﬁnancial resources to support these levels
of care and safety practices. It is important to understand how
these standards can then be reasonably adapted and applied in
LMICs, which often have limited workforce (theme 3) and
ﬁnancial resources (theme 4). Certainly, if standards from
HICs are to be applied in LMICs, then the nephrology
community in the country or region should appropriately
modify the guidelines.Kidney International (2019) 95, S1–S33A major challenge facing LMICs is maintaining safety
and good quality of care in a ﬁnancially responsible way.20
For example, it is worth noting that some ESKD services in
LMICs are provided by small companies, particularly in
smaller towns. This has permitted an expansion of ESKD
care services to patients who otherwise would not have
access to care. Overview of these organizations by gov-
ernment or national nephrology organizations to ensure
adherence to appropriate standards of care is important
and can facilitate the expansion of ESKD care services to
these more remote areas. As already mentioned, some
countries, such as Thailand,125 have achieved cost reduc-
tion by means of a PD-ﬁrst policy. This has been adopted as
a governmental policy and has made universal KRT
coverage possible. PD has a number of features that should
be attractive to LMICs, including lower expense (depend-
ing on local manufacturing and/or low import duties and
taxes), fewer technical demands, greater feasibility of use in
remote regions, reduced need for trained staff, and fewer
management challenges in the setting of natural di-
sasters.126–128 Practical problems in expanding PD pro-
grams include the training of individuals to insert
catheters, the potential risk of infection, and the ability to
obtain dialysate at an acceptable cost. While the latter
problem could be ameliorated by local manufacture of PD
solutions, this has been difﬁcult to realize. Furthermore,
the costs of distribution of supplies has limited the avail-
ability of PD in many LMICs.24,129 It is important to note
that provision of PD involves not only the provision of
dialysis solutions but also the availability of satisfactory
connection ports between PD solutions and the catheter
and appropriate support systems. In addition, it needs to be
appreciated that 10% to 15% of PD patients transfer to HD
each year because of various complications; thus, having an
HD facility available to help manage these patients is
essential.
An important focus of the international nephrology
community in supporting ESKD care in LMICs should be on
the application of well-researched guidelines that are adapted
to the resources and funding available in each country, using
validated tools like ADAPTE130 to ensure that safe, reasonably
good-quality care is provided. Examples include incremental
HD and PD programs, with initiation of dialysis with less
than thrice weekly HD or reduced numbers of PD exchanges
in patients with modest residual renal function.131–135 This
approach is important because it can lead to expanded care of
patients with ESKD. However, careful attention to the amount
of dialysis provided and the maintenance of basic standards of
care remains critically important because limited dialysis will,
in general, provide suboptimal dialysis in patients with no
residual renal function.
New and innovative technology that reduces the cost of
KRT and enhances access to and quality of KRT should be
explored and remain a focus. Activities to deﬁne safe and
minimum standards of dialysis and possible innovative ap-
proaches are summarized in Table 10.S19
Table 10 | Deﬁne and apply minimum and optimal safety and quality standards for PD and HD
Activities Partners Deliverables
Deﬁne safe and minimum standards for sustainable dialysis treatment
- ISN to establish a workgroup to review existing
guidelines and well-established standards of care (in
both HICs and LMICs) focusing on the applicability
and ﬂexibility necessary for care in individual lower-
resource countries
- Integrate local partners, patients, industry, and
global organizations in the discussion
- Disseminate the proposals at regional and national
levels and through WHO, government agencies,
nephrology organizations, and dialysis providers
- Deﬁne the amount of dialysis to be provided and
appropriate timing for the initiation of dialysis
- Consider incremental dialysis for both HD and PD as
way of reducing costs and optimizing care and
quality of life of patients
- Consider possible PD ﬁrst program if PD solutions
can be obtained in a practical, cost-effective manner
- Apply international standards of water treatment
- Consider dialyzer reprocessing with the assurance of
conforming to international standards
- Ensure careful monitoring of outcomes
- Establish appropriate infection control practices,
applying international standards
Affordable Dialysis Project, Kidney Care
Network, PD-ﬁrst programs, hospital
programs, industry, NGOs, PPP, KDIGO,
KDOQI CARI EBP, guidelines from
national renal associations, ISN, AAMI
water standards, international standards
organizations, national societies,
governments, WHO, MOH, national
nephrology organizations, ISPD, ISHD,
universities, US Centers for Disease
Control and Prevention, university-based
global health programs, patient
organizations
- Set of recommendations adapted to local
settings utilizing the ADAPTE130 framework
for:
 Pre-dialysis care, dialysis initiation, dialysis
frequency and dose (HD and PD)
 Recommendations for HD to include water
treatment, dialyzer reuse, machine sterili-
zation, monitoring and reporting safety
and outcomes, infection control
 Recommendations for PD to include
catheter placement, connection systems,
infection control, and possible develop-
ment of local sources of dialysate and
equipment
 Recommendations for infection control to
include prevention of access infection,
infection control standards, patient isola-
tion, vaccination of patients and staff, and
careful monitoring of adverse events
Propose innovative approaches to safe and sustainable dialysis
- Determine feasibility of telemedicine utilization for
staff training, monitoring patients, etc. (theme 3)
International and professional educational
institutions, industry, ISN/ISPD, IPNA,
EuroPD, ISHD, academic medical centers
- Telemedicine consultation for remote areas
- Explore innovative approaches to dialysis therapy,
including creative use of solar energy, innovative
and efﬁcient water treatment, more cost-effective
dialysis machinery, inexpensive manufacture of PD
solutions, and reduction in plastic waste
- Support of new and innovative technologies
Deﬁne safety standards for pediatric facilities
Review existing guidelines ISN, IPNA, ISPD, pediatrics societies Recommendations for pediatric units and care
AAMI, Association for the Advancement of Medical Instrumentation; CARI, Caring for Australasians with Renal Impairment; EBP, evidence based practice; ESKD, end-stage
kidney disease; EuroPD, European Peritoneal Dialysis; HD, hemodialysis; HIC, high-income countries; ISHD, International Society for Haemodialysis; IPNA, International Pae-
diatric Nephrology Association; ISN, International Society of Nephrology; ISPD, International Society for Peritoneal Dialysis; KDIGO, Kidney Disease: Improving Global Out-
comes; KDOQI, Kidney Disease Outcomes Quality Initiative; LMICs, lower-middle–income countries; MOH, Ministry of Health; NGOs, nongovernmental organizations; PD,
peritoneal dialysis; PPP, public-private partnerships; WHO, World Health Organization.
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD careDeﬁne safe and minimum standards for sustainable dialysis
treatment. To deﬁne safe and minimum standards for sus-
tainable dialysis treatment, existing established guidelines
such as Kidney Disease Outcomes Quality Initiative
(KDOQI), KDIGO, European Renal Best Practices, Caring for
Australasians with Renal Impairment (CARI), Canadian So-
ciety of Nephrology, SLANH, National Institute for Health
and Care Excellence (NICE), etc., should be adapted to focus
on their applicability to countries with limited resources in
the context of availability of ﬁnancial and workforce support.
Documents that have been utilized in LMICs, such as Indian
Guidelines,136 as well as various hospital, academic, and
commercial provider recommendations, such as those iden-
tiﬁed in the ISN Collection, provide additional guidance.
Critical vetting and eventual acceptance of these approaches
in individual countries or regions should involve the local
nephrology community, patients, industry, and government
and global health care organizations. Broad dissemination of
the proposals is essential.S20Deﬁne safety standards for pediatric facilities. PD is the
preferred KRTmodality in pediatrics, when transplantation is
delayed or impractical, because it permits more ﬂexibility of
therapy. However in some countries, such as South Africa, if
children with ESKD are judged not to be suitable candidates
for transplant, chronic dialysis is not undertaken because
there is no positive end point and the family may be put in a
ﬁnancially challenged state. Linking an adult and pediatric
unit together may enhance sustainability. Pediatric-speciﬁc
equipment may be difﬁcult to source for stand-alone units
but could be more easily purchased when linked to a larger
adult unit (with increased numbers of patients).
Theme 7: transplantation. Deﬁne the key considerations for
expansion of kidney transplantation as a component of
integrated ESKD care
Transplantation is the preferred modality of care for ESKD in
suitable subjects,6,8 including for children because of the
better quality of life and long-term survival.137 However, thereKidney International (2019) 95, S1–S33
DCH Harris et al.: Global access to ESKD care I SN pub l i c a f f a i r sare wide disparities in access and use and substantial risks to
both donors and recipients associated with poor practices.
According to the Global Observatory on Donation and
Transplantation (GODT), 111 of the 192-member states of
WHO provided data on transplantation activity to the global
registry. Kidney transplants were performed in 102 of the 111
countries.138 Living donor kidney transplants were performed
in 98 countries, and deceased donor transplants in 76.
Figure 5 shows the distribution of kidney transplant rates
around the world. Kidney transplantation is nonexistent in
some parts of the world, including much of Africa and parts
of Southeast Asia, reﬂecting both cultural preferences and
resource limitations. In particular, Africa has a very low
transplant rate, with only 488 kidney transplants performed
(0.4 pmp) in 2015 and a very variable distribution, as many
countries have no transplantation programs.138 The majority
of transplants occur in HICs, and these regions generally have
higher rates of deceased donation. In LMICs, deceased donors
are poorly utilized because of an ineffective organ procure-
ment network, lack of facilities for pre-transplantFigure 5 | Total rate of deceased and live donor transplants in each
Transplantation data, produced by the World Health Organization and S
observatory.org). pmp, per million population.
Kidney International (2019) 95, S1–S33investigation and taking care of potential donors, and poor
public education.139
To achieve expansion, ideally transplantation services
should be integrated into every national program of ESKD
treatment as stated earlier (Table 5). As up to 50% of the
ESKD population are treated by transplantation in several
HICs,140 this can be seen as a potential national benchmark
for eligible patients. All these countries have national
health care schemes and strong deceased kidney donor
programs. For LMICs, an incremental objective relative to
the development and sophistication of their health system
needs to be developed. In addition, efforts should be un-
dertaken to establish regional children transplant centers to
optimize the use of scarce resources. Nearly all newly
established ESKD care programs start with dialysis and
have no transplantation. A policy focused solely on dialysis
will be costly and may result in patients seeking trans-
plantation in an unregulated environment, creating a
market for organ trafﬁcking. Activities to develop trans-
plantation in LMICs are discussed below and in Table 11.region. Reproduced from Global Observatory on Donation and
panish Transplant Organization collaboration (www.transplant-
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Table 11 | Deﬁne the key considerations and role of kidney transplantation as a component of integrated ESKD care
Activities Partners Deliverables
Implement legislation for organ donation and safe transplantation in all countries
- Conduct survey to identify countries that lack or
have inadequate legislation; survey state of
transplant infrastructure
- Identify credentialed centers; identify countries
with LD TX alone and those with LD þ deceased
donor programs
- Partner with local advocates, clinicians, patient
groups to support development of legislation
and lobby governments with respect to illegal
practices (organ trafﬁcking)
WHO, ONT, local patient and support
groups, local health workforce
- Countries identiﬁed with gaps in legislation
- Existing transplant service infrastructure assessed
- Implementation of legislation
- 100% of countries with transplant programs with
legislation for organ donation and transplantation
- Publish transparently all transplant activity in
every country and integrate this information
with dialysis activity
DICG, WHO, WHA, TTS, health
departments
- Increased global capture of activity and outcome
data from integrated dialysis and transplant regis-
tries with systematic reporting of data to ONT-WHO
GODT
- Develop guidance for ethical practice that is
relevant to local resources and cultural factors
ISODP - Established ethical guidance documents that sup-
port institutional best practice
Integrate health care plans that include transplantation
- Identify appropriate transplantation targets (% of
all CKD5 and prevalent KRT patients) for each
region; identify national and regional models for
transplantation
Health departments, TTS, ISN, IPTA,
IPNA, professional societies and
colleges, patient groups
- Region-speciﬁc targets for proportion of KRT pa-
tients for whom transplantation would be appro-
priate; description of regional models
- Include referral pathway for transplantation
where appropriate
- A structured patient education and referral pathway
for living and deceased donor transplantation that
supports integration in each region
Promote organ donation
- Develop handbook of personnel and infrastruc-
ture required for establishment of living and
deceased donation, including community
engagement
- Develop tool kit of guidelines for minimal re-
quirements of a deceased donor program
ISN, TTS, International Society of Organ
Donation and Procurement, WHO
Organ Donor Task Force
- Document outlining the steps for establishment of
deceased donation
- Educational tools for health practitioners and com-
munity members
CKD5, chronic kidney disease stage 5; DICG, Declaration of Istanbul Custodian Group; ESKD, end-stage kidney disease; IPNA, International Paediatric Nephrology Association;
IPTA, International Paediatric Transplant Association; ISN, International Society of Nephrology; ISODP, International Society for Donation and Procurement; KRT, kidney
replacement therapy; LD, living donor; ONT, Spanish Transplant Organization; ONT-WHO GODT, Spanish Transplant Organization-World Health Organization Global Obser-
vatory on Dialysis and Transplantation; TTS, The Transplant Society; TX, transplantation; WHA, World Health Assembly; WHO, World Health Organization.
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD careSubstantial initial investment is required, but this is more
than offset by the lower cost of ongoing treatment and
ﬁnancial returns to the society as a result of improved
rehabilitation. Workforce and training are discussed in
theme 3, and ﬁnance issues and funding models are dis-
cussed in theme 4.
Implement legislation for organ donation and safe trans-
plantation in all countries. Clear, unambiguous legislation
and regulation that recognize and deﬁne brain death and
address commercial transplants are the foundation of a
successful organ donation and transplantation system,
regardless of whether deceased organ donation is occurring
or not, and need to be developed in all countries. It is
essential to protect recipients and donors (from exploita-
tion), transplant professionals, and institutions, and to
eliminate organ trafﬁcking.141 Since the Madrid Resolu-
tion,141 which was built on the WHO guiding principles on
human cell, tissue, and organ transplantation,142 the
Declaration of Istanbul,143 and the Council of Europe
Convention on action against trafﬁcking in human beings,144
there has been an increase in the number of countries with
appropriate legislation. However, in parts of Asia and Africa, thisS22essential component is lacking.138 At present, it remains unclear
how many countries lack appropriate legislation. For those with
legislation there must be agreed-upon deﬁnitions of death to
enable deceased organ donation. Another limiting factor in the
implementation and monitoring of the effectiveness of legisla-
tion is the lack of integration of information systems between
dialysis and transplant activity. The creation and utilization of
registries (see theme 1) that enable linkage between use of
dialysis and transplantation would allow the tracking and
transparent reporting of transplant activity, providing a true
denominator of ESKD and ESKD care, as well as forming the
basis of a tool to identify potential living donors involved in
organ trafﬁcking.
Integrate patient pathways that include trans-
plantation. Extending the detailed discussion of integrated
ESKD care in theme 2, at an institutional level all patients
with stage 5 CKD and ESKD should be considered as po-
tential transplant candidates, and every unit should aspire to
include a structured patient referral pathway for living and,
where appropriate, deceased donor transplantation. For
countries that do not have a national transplant program, the
initial emphasis should be on facilitating living donorKidney International (2019) 95, S1–S33
DCH Harris et al.: Global access to ESKD care I SN pub l i c a f f a i r stransplantation. At a regional level there are opportunities to
develop novel integrated models of care, for example, as is
proposed for the East African Kidney Institute in Nairobi,
Kenya.
Promote donation. Lack of donors remains a major chal-
lenge in both LMICs and HICs. In addition to the substantial
medical infrastructure required, there are social, legal, and
religious hurdles to overcome.145 Even when legal re-
quirements are satisﬁed, public health education and engage-
ment with the community as well as guidance for health
professionals and policy makers is essential. All countries need
to develop pathways that allow potential donors to be identi-
ﬁed in intensive care units and promote opportunities for
donation after death, considering incorporation of presumed
consent, which has been adopted with success in several Eu-
ropean countries.146 The need for advocacy is discussed in
theme 2 and workforce training in theme 3.
Theme 8: conservative care. Deﬁne the key considerations
and development of conservative care as a component of
integrated ESKD care
Supportive and comprehensive conservative care are essential
components of an integrated ESKD care program (Table 5).
The terminology and deﬁnitions for care that optimally
manage symptoms of ESKD are based on the WHO deﬁnition
of palliative care,147 and were agreed on at the KDIGO
Controversies Conference in 201211,148 (Table 1 and
Figure 6). It is imperative that comprehensive conservative
care is not viewed as a low-cost alternative to the development
of KRT programs in LMICs. If there are resource constraints
on the availability of KRT, then management without KRT
should be clearly identiﬁed as either choice-restricted or not,
according to which applies.
Supportive care should be considered for all patients
approaching ESKD as well as those already on KRT in all
countries (Supplementary Table S4). Where high-quality KRTFigure 6 | An overview of the contribution of supportive and compr
disease. Dashed gray lines represent a period of stability, which may be
disease, including information, education, relief of pain and associated sym
kidney disease.
Kidney International (2019) 95, S1–S33can be sustained as part of UHC, it can prolong life for the
majority of people with ESKD; where it cannot, the effec-
tiveness of partially government-funded or self-funded dial-
ysis and kidney transplantation is likely to vary.
Even where high-quality KRT is part of a UHC scheme, for
some older patients with multiple morbidities, observational
evidence suggests dialysis may make little or no difference to
survival or HRQoL compared with comprehensive conservative
care.149–153 The same applies for very young children or those
with multiple morbidities.154–156 Very little is known about the
experiences of people with ESKD who make an informed de-
cision for comprehensive conservative care. Even less is known
about experiences in LMICs where the choice of ESKD care is
restricted by KRTavailability and funding; in these settings, the
issue is compounded by limited availability of trained staff and
essential medication to optimally manage symptoms.
ESKDwas 1 of 21 conditions considered to be contributing to
global avoidable serious health-related suffering in the Lancet
Commission on Palliative Care and Pain Relief,157,158 and its
contribution will increase as populations age and the prevalence
of NCD increases.159 Many of the challenges outlined in the
Commission are relevant to kidney disease, and some of the
greatest opportunities will come from aligning the delivery of
supportive care for people with ESKD, particularly those in
LMICs, to the deliveryofpalliative caremore generally (Table 12).
Activities to enhance the role of conservative care as a
component of integrated ESKD care are discussed below and
in Table 13.
Generate improved information on prognosis and support for
peoplewith ESKDand their families. Prognostic tools to support
ESKD care decision-making are currently limited and require
validation. These tools will require reliable, context-sensitive
information on survival and self-reported people-centered
outcomes such as HRQoL. The evidence base to support pa-
tients and their families is lacking, and requires the following:ehensive conservative care to overall care in end-stage kidney
short or long. Supportive care should be offered at each stage of the
ptoms, nutritional support, and social and spiritual care. CKD, chronic
S23
Table 12 | Challenges and opportunities for integrating supportive care into end-stage kidney disease care
Challenges Opportunities
Establishing education and supply chain
infrastructures for supportive care and
comprehensive conservative care
Join existing education and supply chain infrastructures
established for delivery of palliative care in other conditions,
using telecommunications when relevant
Delivering supportive care in settings where human
resources with the necessary skills are limited
Explore what tasks can be shifted to general physicians, nurses,
physicians’ assistants, other allied health professionals and
community workers
Training key people to deliver effective supportive
care to people with ESKD
Training materials exist and require adapting for delivery in
different settings to a range of health care professionals
Recognizing comprehensive conservative care as a
treatment modality without undermining support
for growth of KRT programs
Clear messaging that comprehensive conservative care should
be part of an integrated, people-centered ESKD service, as set
out by WHO and achieved by other specialties
Adapting guidance and resources to the full range of
settings
Use of the ADAPTE methodology130 to ensure that guidance and
resources are tailored to available resources
Being culturally sensitive to different attitudes
regarding health care decision-making
The ISN has networks with experts across a diverse range of
countries and includes these experts in all activities
ESKD, end-stage kidney disease; KRT, kidney replacement therapy; WHO, World Health Organization.
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD care Careful, context-sensitive evaluation of the effectiveness
and cost-effectiveness of ESKD treatment options
 Validation of tools for estimating prognosis (survival and
HRQoL) utilizing national registries when available (see
theme 1)
 Optimization of tools to support decision-making and
advance care planning
 Development of evidence-based behavioral interventions
to prevent and optimize responses to inter-current
illnesses
Make available evidence-based guidance on
supportive care that is context-sensitive. For LMICs, an
essential package of supportive care resources and in-
terventions should be agreed upon to minimize the burden
of serious (kidney) health-related suffering in people with
ESKD. This would guide policy makers in choosing in-
terventions across different priorities, given trade-offs and
budget constraints, and deciding how these should be
ﬁnanced. This guidance should help provide care to pa-
tients who might not meet local criteria for eligibility for
dialysis so that such patients do not feel “abandoned” by
the health care systems. It must complement and integrate
with all other essential packages to enable incorporation
into a universal essential health care package (see theme 2).
The evidence base for the management of symptoms of
ESKD needs to be developed and guidelines for symp-
tomatic management that can be used by a range of health
care workers adapted for a variety of health care settings.
These would include the “essential bundle” of resources
and interventions (country- and context-speciﬁc) and
recognize the particular challenges of symptom manage-
ment in children and young people with ESKD.
Establish transparent, spiritually and culturally sensitive pro-
cesses and metrics for monitoring equity of access to and quality
of supportive and/or conservative care. See theme 1 for dis-
cussion of deﬁnitions for conservative care and minimumS24data set requirements necessary for registries. All recom-
mendations must respect within- and between-country
differences in attitudes to life, death, and medical decision-
making. This includes, but is not limited to, different views
held by different cultures about end-of-life decision-making.
Resources need to be developed that are culturally speciﬁc,
and health care professionals need to be trained to be
culturally sensitive and informed (i.e., “culturally safe”; see
theme 3 for discussion of training).
Communicate clearly and effectively on the role of supportive
and comprehensive conservative care in advanced stages of
CKD. The choice of terminology around conservative care
can affect patient, public, professional, and policy maker
perceptions and weaken messaging. Poor terminology
could also make integration with established supply chains
and care and education infrastructure more difﬁcult to
achieve. Supportive care must be recognized as an essential,
integral component of ESKD treatment and offered to all
people with advanced stages of CKD, on dialysis, with a
kidney transplant, or receiving comprehensive conservative
care.
Integrate and align supportive and comprehensive care with
existing renal and chronic disease supply chains and infra-
structure. The logistical challenges (e.g., availability of drugs
and health professionals) and costs associated with provision
of services for supportive and comprehensive conservative
care need to be recognized and addressed (see also themes 2–
4). Aligning terminology and ambitions with those of WHO,
the World Bank, and academic commissions (such as the
Lancet Commission)157,158 already working to close gaps in
care should facilitate kidney health to be adopted as one of
their priorities. Examples of where renal services could align
include the following:
 WHO’s Human Resources for Health (HRH 2030)
 WHO’s People Centred Care Framework
 The Lancet Commission on Palliative Care157,158Kidney International (2019) 95, S1–S33
Table 13 | Deﬁne the key considerations and role of conservative care as a component of integrated ESKD care
Activities Partners Deliverables
Improve information on prognosis and support for people with ESKD and their families
Undertake effectiveness and cost-effectiveness
research and develop validated prognostic
tools, relevant to a range of settings
Experts in prognostic modeling, decision-making,
multi-professional experts in supportive and
palliative care, multi-professional experts in adult
and pediatric nephrology, experts in health
economics, ISN and other national and regional
professional associations, patient and parent
organizations, existing academic-ministry
partnerships
Resource hub with tools that can be
adopted or adapted by national
organizations
Make available evidence-based guidance on supportive care that is context-sensitive
Adapt guidelines for supportive and conservative
management of people with advanced CKD for
use by range of health care workers in variety of
settings
Multi-professional experts in ESKD and supportive and
palliative care, guideline writing experts such as
KDIGO and ERBP
A set of guidelines and signposting
tools utilizing the ADAPTE130
framework for adapting to local
context
Establish transparent, spiritually and culturally sensitive processes and metrics for monitoring equity and quality of care in advanced stages of
CKD
- Check WHO key performance indicators for
palliative care and apply to supportive care
where possible
- Study role of tracking change in patient-reported
outcomes over time to guide care
Local and national health service providers and
funders, national renal associations, existing renal
registries
Resource hub to establish registries
(see theme 1) and use data to
raise awareness of the needs of
people with advanced stages of
CKD
Communicate clearly and effectively on the role of supportive and comprehensive conservative care in advanced CKD
- Agree on optimal terminology for engagement
- Develop an effective communication strategy
that can be adapted to a range of settings
Experts in public relations and communication, multi-
professional experts in supportive, palliative, and
advance care planning, ISN and professional
associations, patient and parent organizations
An agreed terminology that works
in all settings as part of a wider
communication strategy
Integrate and align supportive and comprehensive care with existing renal and chronic disease supply chains and infrastructure
- Recognize the logistical challenges and costs
associated with provision of services for sup-
portive and comprehensive conservative care
- Understand any legal or regulatory framework
for providing ESKD treatment
- Consider opportunities from parallel models in
oncology and AIDS, recognizing differences in
onset and duration
Local and national health service providers and
funders, national renal associations, existing renal
registries, ministries and policy makers, existing
academic-ministry partnerships
- Develop costing and “business
case” templates
- Training programs (see theme 3)
CKD, chronic kidney disease; ERBP, European Renal Best Practice; ESKD, end-stage kidney disease; ISN, International Society of Nephrology; KDIGO, Kidney Disease Improving
Global Outcomes; WHO, World Health Organization.
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(NCDI) Poverty Commission (due to be published in 2018)
 The International Children’s Palliative Care Network
 The United Nations Children’s Fund
A number of charities and nongovernmental organizations
have established supply chains and care and/or education in-
frastructures in LMICs. If renal services can partner with these,
it will enhance efﬁciencies and prevent the development of
parallel structures just for people with kidney disease. Exam-
ples of where renal services could align include the following:
 Hospice Africa (www.hospice-africa.org.uk/), which is
already providing palliative care for oncology, AIDS, and
other noncancer end-of-life conditions
 International Association for Hospice and Palliative Care
(www.hospicecare.com), which aims to encourage and
enable each country according to its resources and condi-
tions to develop its own model of palliative care provision
 The African Palliative Care Association (www.african
palliativecare.org), which aims to bring palliative care to
all who need it in Africa through information, integration,
and evidenceKidney International (2019) 95, S1–S33 Partners in Health (www.pih.org), which is facilitating the
integration of NCD services at the district hospital level in
several countries, which could be leveraged to create kidney
care algorithms
Conclusions
In developing action plans to formulate a 5- to 10-year
strategy to improve global access to safe, sustainable, and
equitable integrated ESKD care, we involved stakeholders
with broad and diverse expertise and different professional,
scientiﬁc, and cultural backgrounds. The content of this
document, including the action plans and performance
framework, was developed in a step-wise process, involving
several rounds of internal review, plenary and group discus-
sion at the summit meeting, and subsequent working group
deliberations. Despite this strength, the selection of goals and
activities and their priorities remains subjective, and views
about several issues are likely to differ among members of the
community. Proposed activities include data capture, policy
creation, deﬁnition of quality standards, evidence-based
guidance, capacity-building, implementation, and research.S25
Table 14 | Performance framework
Theme Area of focus Activities Measurable outputs Data sources
1: Estimates of
ESKD burden
and treatment
coverage
Explain the
reasons for and
monitor global
differences in
the incidence
and prevalence
of ESKD, ESKD
care, and
modality of
ESKD care
Establish and enable ESKD registries in
all countries:
 Freely accessible online,
mobile-enabled
 Linked with other data sets and
individual data
Inventory of CKD and ESKD
registries and their data sets
Database reports of ESKD care
resources
Renal registries and other data
sets, ISN SharE-RR committee
2: Advocacy Develop an
approach to
advocate for
integrated
ESKD care in
LMICs
Identify and produce literature
syntheses to support the
development of a national kidney
care program
Document library, including primary
rapid reviews, systematic reviews,
and economic analyses
Cochrane Collaboration,
university-based research
groups
Develop a tool that describes and
justiﬁes the principles behind
establishing a national kidney care
program
Scientiﬁc publication
Technical report
WHO, government ofﬁcials,
nephrology societies, kidney
foundations, patient groups,
academia and health
economists
Develop and disseminate an advocacy
tool kit for stakeholders’ use,
international in outlook but
specialized by country
Key messages, infographics,
economic analyses, case studies
ISN advocacy portfolio, patient
and parent groups, national
kidney foundations, national
and regional nephrology
societies, medical
communities, organ donor
initiatives, major industry
leaders, governments
Educate patients and families about
CKD and ESKD and their rights and
options in all aspects of treatment
Established community groups with
medical staff and families to drive
treatment action campaign
Use World Kidney Day (WKD) to
highlight education and lobby
governments
Annual WKD events
Conduct consumer engagement
workshops in each country
Establish patient ESKD advisory groups
in each country
Annual report detailing consumer
engagement workshops held
Register of patient ESKD advisory
groups established in each
country
Patient and parent
organizations, ISN and other
national and regional
professional associations,
local and national health
service providers and funders,
industry, governments, NGOs
3: Education and
Training or
Workforce
Develop locally
appropriate
strategies to
enhance health
workforce
capacity
Develop robust methodology to collect
data, monitor, and make accurate
projections regarding the renal
workforce
Assess training and education needs of
physicians, nurses, and technicians
Evaluate optimal methods for delivery
of education and training models
and impact of accreditation (included
models applied by other NCDs (e.g.,
AIDS, oncology)
A resource hub with tools adopted
or adapted by national and
regional organizations, academic
centers, international
organizations addressing these
areas with speciﬁc
recommendations of how to
address the local needs with
information gained locally
National and regional
professional associations,
governmental agencies
(national and local), health
care providers, international
organizations, academic
medical centers
4: Financing and
Funding
Models
Develop ﬁnancial
strategies and
funding models
to ensure
equitable
integrated
ESKD care
Enunciate health care ﬁnancing models
of ESKD around the world
Detailed mapping of country-
speciﬁc ESKD health care
ﬁnancing activities
GKHA, ESKD collection,
international, regional,
national societies, WHO,
industry partner documents,
health economic societies
Evaluate their impact on progressivity
and equity
Tool to measure impact of ﬁnancing
models on efﬁciency and
progressivity
Evaluate the economic and social
impact of ESKD treatment including
return on investment
Cost-effectivity analysis tool kits
developed to measure beneﬁts to
society
Best practice recommendations for
affordable treatment of medical
problems in ESKD patients
Narrative case studies showing
evolution and impact of ﬁnancing
models developed
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Table 14 | (Continued)
Theme Area of focus Activities Measurable outputs Data sources
5: Ethics Enunciate ethical
principles
surrounding
ESKD care
Articulate core ethical principles
to guide ESKD policy and
practice
Raise awareness of ethical aspects of
ESKD care among health care
professionals
ESKD ethics statements with other
stakeholders developed
Educational activities and resources
relating to ethics of ESKD patient
care including online resources
developed with universities
WHO, MSF, documents in public
domain on ethical issues in
health care, DICG documents,
international, regional,
national societies, national
guidelines for ESKD care
provision and rationing, global
and national bioethics
societies, international and
national human rights
organizations
Increase research and intervention
guidelines in ethical issues
Established nephrology ethics
leadership, mentorship and
research capacity
Publications addressing ethical issues
in ESKD care in the nephrology
and bioethics communities
Strategic plan for research in the
ethics of ESKD care
6: Dialysis Deﬁne,
recommend,
apply, and
develop a
monitoring
framework for
minimum and
optimal safety
and quality
standards for
peritoneal
dialysis and
hemodialysis
Adaptation of existing published
guidelines from HICs with focus on
the applicability and ﬂexibility
necessary for lower resource
countries
Review existing documents that
currently discuss standards of
care from LMICs
Consider a PD-ﬁrst program after
removal of structural cost barriers
Engage national nephrology
organizations, government, local
partners, patients, dialysis providers,
industry, academic centers and
global organizations in the
discussion
Disseminate the recommendations
to all health care providers
involved in dialysis care,
at national and regional
meetings, and to local and
national health care
agencies
Deﬁne safety standards for children’s
facilities
Metrics for monitoring equity and
quality of access to KRT
Set of recommendations adapted to
local settings for pre-dialysis care,
dialysis initiation, dialysis
frequency and dose (HD and PD),
monitoring and reporting safety
and outcomes, vaccination of
patients and staff, infection
control standards
For HD, to include water treatment,
dialyzer reuse, machine
sterilization, universal
precautions, recommendations
for prevention of access infection
For PD, to include infection control
and monitoring, catheter
placement, connection systems,
and possible development of
local sources of dialysate and
supplies
Affordable Dialysis Project,
Kidney Care Network, PD-ﬁrst
programs, hospital programs,
industry, NGOs, PPP, KDIGO,
KDOQI, various international
guidelines, governmental
health care agencies,
international organizations,
(ISN, IPNA, ISPD) academic
centers, dialysis providers
Explore innovative approaches to
ESRD care
Application of telemedicine
consultation for remote areas
Support of new and innovative
technologies
7: Transplantation Deﬁne the key
considerations
for expansion
of kidney
transplantation
as a component
of integrated
ESKD care
Extend implementation of legislation
to all countries
Enable tracking of dialysis and
transplantation activity
Develop region-speciﬁc attainable
targets of transplant activity, and
how this might be affected by
regional transplant networks
Accurate inventory of countries
lacking legislation
An integrated database of dialysis
and transplant activity
A guide to appropriate levels of
transplantation to support
growth
International registries and
GKHA
Integration of existing
dialysis and transplant
registries
Cost-economic models
of the investment or
payback based on
LMICs data
Promote deceased organ donation
(DOD)
A guide and set of tools that outline
the steps required to establish
DOD
Reported experience and
barriers and resource
requirements from
existing programs and
LMICs that have achieved
DOD
(Continued on next page)
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Table 14 | (Continued)
Theme Area of focus Activities Measurable outputs Data sources
8: Conservative
care
Deﬁne the key
considerations
and
development of
conservative
care as a
component of
integrated
ESKD care
Information on prognosis and support
for ESKD
A validated prognostic tool for
dialysis and conservative care
outcomes
Guidelines that can be adapted
for different resource settings
Key performance indicators for
conservative care
Published terminology
Collaborative partnerships to be
developed and functioning
International registries
capturing key metrics
Multi-professional experts,
patients and carersContext-sensitive guidance for
supportive care
Metrics for monitoring equity and
quality of conservative care
Agreed terminology that underpins
communication
Alignment of care with existing chronic
disease infrastructure
WHO performance indicators for
palliative care, expert opinion
from renal and chronic
disease groups
Sharing of knowledge, training
and infrastructure
CKD, chronic kidney disease; DICG, Declaration of Istanbul Custodian Group; ESKD, end-stage kidney disease; GKHA, Global Kidney Health Atlas; HD, hemodialysis; HICs, high-
income countries; IPNA, International Paediatric Nephrology Association; ISN, International Society of Nephrology; ISPD, International Society for Peritoneal Dialysis; KDIGO,
Kidney Disease: Improving Global Outcomes; KDOQI, Kidney Disease Outcomes Quality Initiative; KRT, kidney replacement therapy; LMICs, lower-middle–income countries;
MSF, Médecins Sans Frontières; NCDs, noncommunicable diseases; NGOs, nongovernment organizations; PD, peritoneal dialysis; PPP, private-public partnerships; SharE-RR,
sharing expertise to support the setup of renal registries; WHO, World Health Organization.
I SN pub l i c a f f a i r s DCH Harris et al.: Global access to ESKD carePartners in these endeavors will include patients, govern-
mental agencies, policy makers, academic institutions, health
care institutions, industry partners, research funding agencies,
clinicians, and researchers.
After identiﬁcation of existing gaps in knowledge, clin-
ical practice, and access to ESKD care around the globe,
action plans were developed to improve monitoring of
ESKD and its therapeutic options; to advocate for
expanded and equitable ESKD care appropriate to the
context of local resources, health priorities and culture; to
build capacity by training a diverse workforce; to deﬁne
standards for safe, sustainable, and ethical ESKD care; and
to establish dialysis, transplantation, and comprehensive
conservative care as complementary treatment choices for
patients with ESKD. These plans and associated activities
will need to be adapted to the needs of individual coun-
tries, based on geographical, socioeconomic, cultural, and
political considerations. Finally, the participants reiterated
the need to embed improved ESKD care in the overall
environment that prioritizes prevention and early treat-
ment of kidney diseases.
Granularity within each of the activities and deliverables
will be developed over the coming months in conjunction
with various partners identiﬁed in the action plans, and with
those partners a detailed strategic plan deﬁned for imple-
mentation over the next 5 to 10 years. A performance mea-
surement framework will be developed for qualitative and
quantitative assessment of progress in implementation of each
component of the strategy, and to hold the nephrology
community and other stakeholders to account. The perfor-
mance framework is presented here at a high level (Table 14),
and will be ﬂeshed out as the strategic plan is ﬁnalized. We
perceive a broad recognition among all those involved in the
care of kidney patients of the importance of improving global
access to safe and sustainable integrated ESKD care, and that
the inclusive involvement of all relevant individuals and
groups in implementation and tracking of progress will lead
to improved care and outcomes for patients with ESKD
globally.S28APPENDIX
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